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ABSTRACT 
Acetaminophen (APAP) is a widely used analgesic, which is safe at 
therapeutic levels. APAP is mainly conjugated with glucuronic acid and sulfate 
to form water-soluble, nontoxic metabolites. Only a small portion of APAP is 
metabolized by P-450 isoenzymes, thereby forming the reactive metabolite 
N-acetyl-p-benzoquinone imine (NAPQI). NAPQI can react with sulfhydryl 
groups such as GSH. After APAP overdose, hepatic GSH is dramatically 
reduced, and NAPQI is able to bind to cellular proteins including 
mitochondrial proteins. This protein binding results in mitochondrial 
dysfunction and reactive oxygen species formation. This chain of events 
eventually leads to necrotic cell death of hepatocytes. My goal was to 
investigate the mechanisms and signaling pathways of APAP-induced cell 
necrosis in the liver, and to identify therapeutic approaches to prevent liver 
failure. Three protective strategies were investigated in detail:  
1) Glutathione (GSH) and N-acetylcysteine (NAC) 
2) Metallothionein (MT) 
3) C-jun N-terminal kinase (JNK) inhibitor 
1) Both in humans and in experimental animals, NAC is used as an antidote 
against APAP-induced liver injury. The doses of NAC that are being used 
clinically and experimentally are higher than needed for re-synthesis of 
hepatic GSH levels. In fact, our laboratory demonstrated that lower doses of 
GSH are highly effective in protecting against APAP toxicity. Therefore, I 
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investigated whether there is a difference between the efficacy of NAC and 
GSH in protecting against APAP hepatotoxicity. Our data indicate that the 
amino acids supplied with the delayed treatment of the same dose of GSH or 
NAC are used for the re-synthesis of hepatic glutathione at similar levels, 
which protect against APAP-induced reactive oxygen species and 
peroxynitrite in the mitochondria. However, excess amino acids derived from 
GSH also serve as energy substrates for the Krebs cycle, which results in 
better protection against APAP hepatotoxicity than NAC treatment. Thus, the 
optimal protection by delayed GSH or NAC treatment involves the 
combination of two mechanisms, which are the accelerated recovery of 
mitochondrial GSH levels and the support of the mitochondrial bioenergetics.   
2) Metallothionein (MT) expression attenuates APAP-induced liver injury; 
however, the mechanism of this protection remains incompletely understood. 
To address this issue, mice were treated with ZnCl2 for three days to induce 
MT. Twenty-four hours after the last dose of zinc, the animals received 300 
mg/kg APAP. We found that the protective effect of MT in vivo was not due to 
the direct scavenging of reactive oxygen species and peroxynitrite. In addition, 
zinc treatment had no effect on the early GSH depletion kinetics after APAP 
administration, which is an indicator of the metabolic activation of APAP to its 
reactive metabolite NAPQI. MT was able to effectively trap NAPQI by 
covalent binding. We conclude that MT scavenges some of the excess 
NAPQI after GSH depletion and prevents covalent binding to cellular proteins, 
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which is the trigger for the propagation of the cell injury mechanisms through 
mitochondrial dysfunction and nuclear DNA damage.  
3) C-jun N-terminal kinase (JNK) has been suggested to contribute to 
APAP-induced liver injury. The postulated mechanism of JNK involvement 
was the promotion of mitochondrial Bax translocation, which triggers 
mitochondrial outer membrane pore formation and results in the release of 
intermembrane proteins such as apoptosis inducing factor (AIF) and 
endonuclease G (EndoG). However, it was reported that Bax-deficient mice 
were only temporally protected against APAP-induced liver injury (Bajt et al., 
2008). In contrast, the protective effect of a JNK inhibitor was observed 
consistently up to 24 h. Therefore, additional mechanisms of injury involving 
JNK activation need to be considered. To address this issue, I treated mice 
with the JNK inhibitor, SP600125 1h before APAP (600 mg/kg). SP600125 
reduced peroxynitrite formation; however, it did not have any significant effect 
on the level of nitrate and nitrite in plasma. Moreover, L-N-(1-iminoethyl)lysine 
(L-Nil), a specific iNOS inhibitor, attenuated neither plasma nitrate and nitrite 
levels nor hepatic injury after APAP injection. Taken together, SP600125 
reduced peroxynitrite formation by decreasing superoxide formation. In 
summary, my investigation demonstrated that JNK is a critical factor for Bax 
translocation, which causes mitochondria outer membrane pore formation. In 
addition, JNK accelerates peroxynitrite generation via induction of superoxide 
formation.  
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In conclusion, I demonstrated the efficacy of three protective strategies 
against APAP-induced hepatotoxicity: Mechanism of protection A: Preventing 
NAPQI binding to proteins (e.g., induction of MT gene expression); 
Mechanism of protection B: Scavenging (GSH, NAC) or reducing (JNK 
inhibition) the formation of reactive oxygen species; and Mechanism of 
protection C: Supplying mitochondrial energy substrates (GSH, NAC).  
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°C   Celsius 
AIF  Apoptosis inducing factor 
ALT  Alanine aminotransferase 
AMAP  3’-hydroxyacetanilide 
ANT  Adenine nucleotide translocator 
Anti-Fas Agonistic anti-Fas antibody 
APAP  Acetaminophen 
ASC Apoptosis-associated speck-like protein containing caspase 
recruitment domain 
Bad   Bcl-2 associated death promoter 
Bak   Bcl-2 antagonist/killer 1 
Bax   Bcl-2 associated X protein 
Bcl-2         B cell lymphoma 2 
Bcl-xL   Bcl-2 like 1 
BH3   Bcl-2 homology 3 
Bid   BH3 interacting domain 
Bik   Bcl-2 interacting killer 
Bim   Bcl-2 interacting mediator of cell death 
Bok   Bcl-2 related ovarian killer 
CAD   Caspse activated DNase 
CAMs  Cellular adhesion molecules 
CARD  Caspase recruitment domains 
CK  Creatine kinase  
COX  Cyclooxygenase 
CsA  Cyclosporin A 
CyD  Cyclophilin D 
DMSO  Dimethyl sulfoxide 
DNase  Deoxyribonuclease  
DTNB  Dithionitrobenzoic acid  
ER   Endoplasmic reticulum 
Endo G   Endonuclease G 
GdCl3   Gadolinium chloride 
GPx  Glutathione peroxidase 
GSH  Glutathione  
h  Hour 
HK  Hexokinase  
HOCl  Hypochlorous acid 
ICAM-1  Intercellular cell adhesion molecules 
 11 
IFN-γ    Interferon-γ   
IgG   Immunoglobulin G 
IL-  Interleukins 
IL-1 R  IL-1 receptor 
IL-1RA  IL-1 receptor antagonist 
IM  Inner mitochondrial membrane 
JNK  c-Jun N-terminal protein kinase 
kDa   Kilodaltons 
KO mice Knockout mice 
L-Nil  L-N6-(1-iminoethyl)-lysine  
LPO  Lipid peroxidation  
LPS  Lipopolysaccharide 
M   Molar 
Mcl-1   Myeloid cell leukemia-1 
Min   Minute 
mL   milliliter 
MOMP  Mitochondrial outer membrane permeabilization  
MPO  Myeloperoxidase 
MPT  Mitochondrial membrane permeability transition  
NAC  N-acetylcysteine 
Nalp3  NACHT, LRR, and pyrin domain-containing protein 3  
NAPQI  N-acetyl-p-benzoquinone imine 
NK  Natural killer 
NKT  Natural killer with T-cell receptors 
NO  Nitric oxide 
OM  Outer mitochondrial membrane 
p53   Protein 53 
PBR  Peripheral-type benzodiazepine receptor  
PC  Pyruvate carboxylase 
PDH  Pyruvate dehydrogenase 
Prx  Peroxiredoxin 
Puma   p53-upregulated modulator of apoptosis 
ROS  Reactive oxygen species 
Smac  Second mitochondria-derived activator of caspases 
SODs  Superoxide dismutases 
tBid   Truncated Bid 
TLR  Toll-like receptor  
TNF R  Tumor necrosis factor receptor 
TNF-Rp55 TNF receptor with a molecular weight of 55 kDa  
TNF-α  Tumor necrosis factor α 
TOM  Translocase of the outer mitochondrial membrane 
TUNEL Terminal deoxynucleotidyl transferase-mediated dUTP 
nick-ending labeling 
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U   Unit 
VCAM-1 Vascular cell adhesion molecule 
VDAC  Voltage-dependent anion chennel 
WT   Wild type 
ZVAD-FMK Benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone 
µg   Microgram 




CHAPTER 1: GENERAL INTRODUCTION 
1) APAP-induced cell death: apoptosis versus oncotic necrosis  
It has been discussed whether APAP overdose induces apoptotic or necrotic 
cell death. Apoptosis and necrosis are defined by characteristic morphological 
changes of the cell (table 1). In apoptotic cell death, a cell undergoes 
shrinkage, shows chromatin condensation in the nucleus, and eventually 
breaks down into apoptotic bodies. In contrast, oncotic necrosis is 
characterized by cell swelling, chromatin flocculation, and absence of vesicle 
formation. It has been reported that apoptosis has a critical role in 
APAP-induced liver failure (Ferret et al., 2001; Zhang et al., 2000b). It was 
observed that after APAP administration, the pro-apoptotic Bcl-2 family 
member Bax translocated to mitochondria (Bajt et al., 2008), mitochondrial 
cytochrome c was released (Bajt et al., 2008), and DNA fragments could be 
detected on an agarose gel (Cover et al., 2005b), all of which occur in 
apoptotic cell signaling. However, based on morphological evidence, APAP 
appears to induce oncotic necrosis in the centrilobular area in vivo (Gujral et 
al., 2002). In addition, none of the above mentioned indicators are specific for 




Apoptosis Oncotic Necrosis 
Membrane blebbing, but no loss of 
integrity 
Loss of membrane integrity 
Aggregating of chromatin at the nuclear 
membrane 
Flocculation of chromatin 
Cell shrinkage Swelling of the cell and lysis 
Formation of membrane bound vesicles 
(apoptotic bodies) 
No vesicle formation, complete 
lysis 
No disintegration of organelles: organelles 
remain intact 




Morphological characteristics for apoptosis and oncotic necrosis 
 
2) The mechanism of APAP-induced hepatotoxicity 
a) APAP metabolism and protein binding 
APAP is eliminated mainly as nontoxic conjugates with glucuronic acid via 
glucuronyltransferase (Nelson, 1990, 1995) and excreted into bile through the 
canalicular multidrug resistance-associated protein 2 (Mrp2, Abcc2) or into 
blood through Mrp3 (Abcc3) (Xiong et al., 2000). APAP is also conjugated 
with sulfate through sulfotransferases and is eliminated into bile mainly via 
Mrp2, and to lesser degree via breast cancer resist protein (BCRP, ABCG2) 
(Zamek-Gliszczynski et al., 2005). A small part of the APAP dose is 
metabolized to a reactive metabolite NAPQI by CYP2E1, CYP1A2, and                       





Scheme for APAP overdose metabolism. Modified from (James et al., 
2003b). 
 
It has been shown that NAPQI reacts very rapidly with GSH (k1 = 3.2 X 10
4 
M-1 s-1 at pH 7.0) (Coles et al., 1988). Therefore, after NAPQI formation 
following APAP overdose, the GSH concentration becomes very low in the 
centrilobular cells (Figure 1.1). Following depletion of GSH, remaining NAPQI 
reacts with cysteinyl sulfhydryl groups on proteins to produce the 
corresponding 3-(cystein-S-yl)acetaminophen adduct. No other sites of 
binding to protein have been identified in vivo (Roberts et al., 1987). It has 
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been demonstrated by mass spectrometry that approximately 40 proteins can 
react with APAP metabolites (Qiu et al., 1998). The covalent modification of 
cellular proteins was originally thought to be the cause of necrotic cell death, 
which is supported by the fact that prevention of covalent binding can reduce 
cell death (Jollow et al., 1973; Mitchell et al., 1973a; Mitchell et al., 1973b). 
However, it was reported that total binding to cellular proteins may be less 
relevant than selective modifications of specific critical targets. The 
regioisomer of APAP, 3’-hydroxyacetanilide (AMAP) can cause GSH depletion 
and a similar degree of covalent binding to cellular proteins as APAP; however, 
AMAP does not cause liver injury (Tirmenstein and Nelson, 1989). 
Furthermore, APAP administration depleted mitochondrial GSH to a greater 
extent than AMAP. Moreover, APAP metabolites bound more extensively to 
mitochondrial proteins than AMAP (Tirmenstein and Nelson, 1989). This 
indicated that mitochondria are a target for covalent binding of NAPQI, which 
is a critical event in APAP-induced hepatotoxicity (Gupta et al., 1997; Pumford 
et al., 1990; Tirmenstein and Nelson, 1989). 
b) Mitochondria respiration 
Succinate dehydrogenase (associated with respiratory complex II) is very 
sensitive to NAPQI because it contains a number of cysteine-rich sulfur 
clusters. In addition, NAPQI inhibits NADH dehydrogenase (complex I) to a 
lesser extent. However, NAPQI does not have any effect on the activities of 
either ubiquinol-cytochrome c oxidoreductase (complex III) or cytochrome 
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oxidase (complex IV) in hepatocytes. (Burcham and Harman, 1991). 
Moreover, exposure of both rat and mouse liver mitochondria to NAPQI has 
been shown to result in the irreversible inhibition of mitochondrial respiration 
(Esterline et al., 1989; Ramsay et al., 1989). Taken together, these data 
suggest that NAPQI binds to mitochondrial respiration chain complexes and 
disrupts energy homeostasis, which contributes to APAP-induced 
hepatotoxicity.  
c) Oxidative stress 
Inhibition of mitochondrial respiration by NAPQI causes accumulation of 
reactive oxygen species (ROS). ROS are generated by one electron 
reduction of molecular oxygen (3O2). During the spontaneous dismutation of 
superoxide (O-2), singlet oxygen (
1O2) plus hydrogen peroxide are formed. 
Superoxide reacts with Cu2+/Zn2+ - or Mn3+ -superoxide dismutase 
(SOD) in the cytosol and nucleus or in the mitochondria, respectively (Slot et 
al., 1986), which produced molecular oxygen (3O2) and hydrogen peroxide 
(H2O2). H2O2 is more stable than O-2 and quickly diffuses across membranes. 
In the presence of ferrous iron (Fe2+), H2O2 can be reduced to the highly 
reactive OH
. 
radical (Fenton reaction), which initiates lipid peroxidation (LPO). 
Uchiyama et al demonstrated that ROS induce the release of chelatable iron 
from lysosomes. The iron is taken up by mitochondria via the calcium 
uniporter (Uchiyama et al., 2008). Wendel and coworkers showed that APAP 
metabolism triggers massive LPO, which corresponded with hepatotoxicity in 
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vitamin E-dificient mice (Wendel and Feuerstein, 1981; Wendel et al., 1979). 
However, mice fed a normal diet showed only minor LPO (Knight et al., 2003). 
Moreover, enhancing levels of α-tocopheryl acetate in the liver by either 
repeated injections of  α-tocopherol or by feeding high d-α-tocopheryl acetate 
diet did not have any effect on APAP-induced liver injury (Knight et al., 2003). 
Taken together, LPO may not be involved in APAP-induced liver toxicity.  
However, if nitric oxide (NO) is present, O-2 reacts with NO and forms 
peroxynitrite (ONOO-), which causes nitration of proteins (Belizario et al., 
2007; James et al., 2003a). It has been reported that peroxynitirite formation, 
which can be detected by immunohistochemical staining against 
anti-nitrotyrosine protein adducts, occurrs in the mitochondria after APAP 
injection (Cover et al., 2005b). The rate of peroxynitrite formation depends on 
the concentrations of both NO and superoxide (Koppenol, 1998; Squadrito 
and Pryor, 1998). The source of NO formation remains unclear. Hepatocytes, 
stellate cells and Kupffer cells express inducible nitric oxide synthase (iNOS) 
and endothelial cells constitutively express eNOS (Muriel, 2000). It was 
reported that APAP-induced liver toxicity was significantly lower in eNOS 
knockout (KO) and iNOS KO mice compared to wild type (WT) animals. In 
addition, plasma nitrate and nitrite levels were higher in WT animals than in 
both KO animals (Salhanick et al., 2006). Although Michael et al. showed that 
serum ALT levels were lower in iNOS knockout mice, which is consistent with 
the previous data, there was no significant difference in tissue injury as 
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assessed by histology (Michael et al., 2001). In terms of NOS inhibitors, a 
selective iNOS inhibitor, L-N6-(1-iminoethyl)-lysine (L-Nil) did protect against 
APAP-induced liver injury; however, a nonselective NOS inhibitor, 
NG-nitro-L-arginine methyl ester (L-NAME) did not (Ito et al., 2004). Others did 
not find protection with various iNOS inhibitors (Hinson et al., 2002). 
Therefore the source of NO during APAP-induced liver injury needs further 
investigation.  
Mimitochondrial DNA (mtDNA) may be a target of ROS due to close 
proximity to the electron transport chain and a lack of protective histones (Ott 
et al., 2007a). mtDNA is essential for electron transport and ATP generation 
by oxidative phosphorylation. Therefore, mtDNA damage can cause 
respiratory dysfunction (Anderson et al., 1981). It was shown that 
mitochondrial oxidant stress can cause depletion of mitochondrial DNA 
(mtDNA) in several in vivo models, such as alcohol binge drinking (Mansouri 
et al., 1999) and tacrine hepatotoxicity (Mansouri et al., 2003). In the APAP 
model, there is a significant reduction of mtDNA between 3 and 12h after 
APAP administration. However, scavenging of peroxynitrite with GSH partially 
prevented the loss of mDNA, suggesting that peroxynitrite was, at least in part, 
responsible for the mtDNA loss (Cover et al., 2005b).  
d) Antioxidant defense 
There are many antioxidant defense systems to handle both the continuous 
formation of reactive oxygen and reactive nitrogen species in physiological 
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and pathophysiological conditions. For example, superoxide is removed by 
superoxide dismutases (SODs). Cu2+/Zn2+-SOD (SOD1) is mainly located in 
the cytosol and nuclear matrix, and Mn3+-SOD (SOD2) is present in the 
mitochondria (Slot et al., 1986). The high intracellular SOD levels (approx. 10 
µM) keep the steady-state levels of superoxide in the range of 1 to 10 pM 
(Cadenas and Davies, 2000; Koppenol, 1998). What is the advantage of high 
SOD expression when superoxide alone is not very toxic? The main reason 
for the importance of SOD might be to limit peroxynitrite generation (Koppenol, 
1998; Squadrito and Pryor, 1998). The rate of depletion for superoxide is 
20000/sec with SOD (approx. 10 µM), but only 200/ sec with NO (approx. 10 
nM under physiological conditions) (Squadrito and Pryor, 1998). Therefore, 
SOD prevents peroxynitrite formation under physiological conditions.  
 Hydrogen peroxide formed by SOD is detoxified by catalase and 
glutathione peroxidase (GPx). Most of the cellular catalase is located in 
peroxisomes, and the main function of the enzyme is to metabolize hydrogen 
peroxide generated by oxidases in the peroxisomes. However, it was reported 
that catalase may be constitutively expressed in rodent liver mitochondria 
(Salvi et al., 2007). Further, the 30% reduction of catalase activity has been 
demonstrated after APAP overdose (Lores Arnaiz et al., 1995), and this might 
be involved in APAP-induced hepatotoxicity. These results suggested that 
catalase could be a key antioxidant enzyme during APAP hepatotoxicity. 
However, whether this small reduction in catalase activity has any 
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pathophysiological relevance remains unclear because massive catalase 
induction did not reduce APAP hepatotoxicity (Chen et al., 2002). Another 
antioxidant enzyme, glutathione peroxidase (GPx-1) is located in the cytosol 
(75%) and mitochondria (25%), and it was reported that cellular GPx could 
also reduce peroxynitrite in vitro (Sies et al., 1997). In spite of this, 
APAP-induced peroxynitrite-dependent injury was not increased in GPx-1 
knockout mice (Knight et al., 2002). It is known that cellular GPx-1 can reduce 
peroxides, including hydrogen peroxide and organic peroxides 
(Brigelius-Flohe, 1999), and this requires GSH as a cofactor, but has a low 
specificity for peroxide. During the reduction of the peroxide, GSH is oxidized 
to glutathione disulfide (GSSG). Normally GSSG is reduced back to GSH by 
glutathione reducatase and NADPH (>95%) or excreted into bile and plasma 
from hepatocytes (<5%) (Lauterburg et al., 1984). However, extreme 
oxidative stress can overwhelm these processes leading to accumulation of 
GSSG, because the glutathione reductase is the rate-limiting step of this cycle. 
In addition, GSSG can not be exported from mitochondria although 
mitochondria take up and release GSH (Olafsdottir and Reed, 1988).  
 GSH is the most important water-soluble antioxidant and it is used as 
a cofactor for GPxs and GSTs. Other low-molecular-weight antioxidants 
include ascorbate (vitamin C), α-tocopherol (vitamin E). GSH is not only 
present in the cytosol, but also in mitochondria, which contain 15% of total 
cellular GSH (Fernandez-Checa and Kaplowitz, 2005). GSH is a tripeptide of 
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glutamic acid, glycine and cysteine, which is formed in the cytosol by two 
ATP-dependent enzymes, γ-glutamylcysteine synthetase and GSH 
synthetase (Figure 1.2). Because of its γ-glutamyl bond, GSH can be 
degraded only by γ-glutamyltranspeptidase, which is located on the surface of 
epithelial cells in the kidney, lung, and intestine and in the biliary tract. It was 
previously shown that the half-life of intravenously injected GSH in plasma is 
less than 5 min in starved animals (Wendel and Jaeschke, 1982). Therefore, 
injected GSH is degraded in the kidney and the amino acids are re-absorbed 





GSH synthesis.  
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e) Innate immunity 
The innate immune response is the first line of defense against microbes and 
toxins (Janeway and Medzhitov, 2002). Kupffer cells, the resident 
macrophages in the liver, are highly phagocytic and are able to remove 
microorganisms. In addition, they can produce inflammatory mediators 
leading to invasion of inflammatory cells, such as neutrophils, monocytes, T 
and B lymphocytes as well as natural killer (NK) cells in the liver. Neutrophils 
accumulate within the hepatic microvasculature before they extravasate into 
liver parenchyma (Ramaiah and Jaeschke, 2007). Many inflammatory 
mediators, such as tumor necrosis factor α (TNF-α), interleukin-1 (IL-1), CXC 
chemokine and platelet activating factor (PAF) can cause neutrophil 
accumulation within the hepatic microvasculature (Jaeschke and Hasegawa, 
2006). Chemokines represent a large family of chemotactic peptides that can 
be produced by hepatocytes, sinusoidal endothelium, cholangiocytes, Kupffer 
cells and stellate cells (Ramaiah and Jaeschke, 2007). The exposure to 
inflammatory mediators triggers mobilization of secretory granules and 
increased adhesion molecule expression on neutrophils, resulting in priming 
and activation of cells. In general, neutrophil activation/accumulation within 
sinusoids and postsinusoidal venules typically does not cause liver damage 
(Ramaiah and Jaeschke, 2007).  
Extravasation into the parenchyma is required to fully activate 
neutrophils, which can generate reactive oxygen species and cause tissue 
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damage (Chosay et al., 1997). Normally, the adhesion molecules β2 integrin/ 
intracellular cell adhesion molecules (ICAM)-1 and β1 integrin/vascular cell 
adhesion molecule (VCAM)-1 interactions are involved in the migration of 
neutrophils into parenchyma, which is a prerequisite of neutrophil-mediated 
injury (Chosay et al., 1997; Essani et al., 1997; Essani et al., 1995). However, 
during extensive endothelial damage resulting from ischemia-reperfusion, 
neutrophils can extravasate directly into the parenchyma without cellular 
adhesion molecules (CAMs) (Farhood et al., 1995). Independent of the 
condition of the endothelial cell barrier, signaling from parenchymal cells or 
extravasated neutrophils is required for neutrophil migration. It was reported 
that lipid peroxidation products including lipid aldehydes are potent 
chemotactic factors for neutrophils (Jaeschke, 2000). In addition, CXC 
chemokines are chemotactic factors (Okaya and Lentsch, 2003), which have 
been shown to contribute to the promotion of neutrophilic hepatitis during 
ischemia-reperfusion injury (Colletti et al., 1996; Lentsch et al., 1998). 
However, the massive amounts of CXC chemokines generated in 
parenchymal cells during endotoxemia do not cause neutrophil extravasation 
when endotoxin is administered alone (Dorman et al., 2005). Moreover, CXC 
chemokines, MIP-2 and KC, in circulation are much less effective in recruiting 
neutrophils into the hepatic vasculature and activation of neutrophils in vivo, 
compared to cytokines or complement (Bajt et al., 2001). Therefore, further 
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studies are necessary to investigate the mechanism of neutrophils activation 
and extravasation.  
Once extravasated, the neutrophils will adhere to the target, i.e. 
parenchymal cells. Upon activation, neutrophils generate superoxide via 
NADPH oxidase which is a multicomponent enzyme system that assembles 
at the cell membrane (El-Benna et al., 2005). Superoxide dismutases 
converts superoxide to hydrogen peroxide, which can be used by 
neutrophil-derived myeloperoxidase (MPO) to generate a potent oxidant, 
hypochlorous acid (HOCl) (El-Benna et al., 2005). Hypochlorous acid also 
can react with amino groups forming toxic chloramines (Bilzer and Lauterburg, 
1991). In addition to ROS, neutrophil-derived serine proteases are known to 






Proposed mechanisms for neutrophil-mediated liver pathology.  
Modified from (Jaeschke, 2006) 
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The involvement of innate immunity in APAP-induced hepatotoxicity is 
controversial. It was reported that APAP treatment induced Kupffer cell 
activation (Laskin and Pilaro, 1986) and migration of neutrophils into the liver 
(Lawson et al., 2000). Kupffer cells have been implicated in the mechanism of 
hepatocellular injury and peroxynitrite formation after APAP overdose (Laskin 
et al., 1995; Michael et al., 1999). Mice treated with APAP plus gadolinium 
chloride (GdCl3), a macrophage inhibitor, decreased hepatotoxicity as 
evidenced by lower ALT levels (Michael et al., 1999). In contrast, mice treated 
with APAP plus liposome-entrapped clodronate, an effective Kupffer 
cell-depleting agent, increases APAP-induced hepatotoxicity (Ju et al., 2002). 
Ju et al. showed that the difference between gadolinium chloride treated mice 
and liposome-entrapped clodronate is IL-10 level in the liver. IL-10, which is 
produced by macrophages is completely inhibited by the Kupffer 
cell-depleting agent, liposome-entrapped clodronate treated group (Ju et al., 
2002). These results are supported by the fact that IL-10 KO mice are more 
susceptible after APAP administration via induction of iNOS mRNA 
expression. Furthermore, serum nitrite-nitrate levels were significantly 
elevated in IL-10 KO mice after APAP administration (Bourdi et al., 2002). 
Moreover, it was reported that peroxynitrite formation was increased in 
sinusoidal endothelial cells during the early phase after APAP administration 
(Knight et al., 2001). However, GdCl3 treatment had no effect on peroxynitrite 
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formation in vascular endothelial cells or parenchymal cells (Liu et al., 1995). 
This suggests an intracellular oxidant stress and peroxynitrite formation in 
sinusoidal endothelial cells rather than a Kupffer cell-derived oxidant stress. 
Furthermore, the most active Kupffer cells are located in the periportal area 
(Bautista et al., 1990; Jaeschke et al., 1991) and activation of these cells in 
ischemia-reperfusion model results in a periportal to midzonal injury 
(Jaeschke and Farhood, 1991). In contrast, APAP causes strict centrilobular 
necrosis. Therefore, overall these results indicate that Kupffer cells are not a 
relevant source of vascular oxidant stress during APAP hepatotoxicity.  
 It is controversial whether polymorphonuclear leukocytes 
(neutrophils) are relevant for APAP-induced liver injury. The presence of 
neutrophils in the areas of necrosis after APAP overdose injection was first 
demonstrated by Mitchell et al (Mitchell et al., 1973a), but the 
pathophysiological relevance of this observation was unclear. Cover et al 
showed that the location of most neutrophils was outside the area of necrosis, 
which was in contrast to models where neutrophils caused liver cell injury 
(Cover et al., 2006). Inflammatory cytokines and CXC chemokines were also 
increased after APAP administration (Horbach et al., 1997; Lawson et al., 
2000; Takada et al., 1995); however, there was no upregulation of Mac-1 
(CD11b/CD18) on circulating neutrophils. Moreover, an anti-CD18 antibody 
had no protective effect against APAP overdose (Lawson et al., 2000). In 
addition, mice deficient in ICAM-1, a counter receptor for Mac-1, were not 
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protected against APAP-induced hepatotoxicity (Cover et al., 2006). Taken 
together, neutrophil migration into the parenchyma might not be relevant to 
APAP-induced hepatotoxicity. In terms of oxidative stress caused by 
neutrophils, despite the substantial number of neutrophils transmigrated into 
hepatocytes, there was no evidence for the generation of relevant amounts of 
HOCl-modified proteins, which is a specific marker for neutrophil-derived 
oxidant stress (Cover et al., 2006). Furthermore, animals deficient in gp91 
phox, an essential protein of activated NADPH oxidase complex in 
phagocytes, did not show any protective effect after APAP administration 
(James et al., 2003b). In support of this finding, a chemical inhibitor of 
NADPH oxidase, DPI, did not decrease APAP-induced hepatotoxicity (Cover 
et al., 2006). Together, these data lead to the conclusion that neutrophils do 
not actively contribute to the injury.  
 Natural killer (NK) and natural killer T (NKT) cells, which play a role in 
defense against viral infection and tumor transformation, might be involved in 
APAP-induced liver toxicity. The liver contains a resident lymphocyte 
population, composed of 5-10% NK cells and 30-40% NKT cells in mice. (Gao 
et al., 2008; Gao et al., 2009). Liu et al. showed that depletion of NK, NKT 
cells by anti-NK1.1 significantly reduced APAP-induced hepatotoxicity by 1) 
reduction of interferon-γ (IFN-γ) secretion, which modulates inflammatory 
chemokine formation, 2) reduction of neutrophil accumulation, and 3) 
reduction of Fas ligand expression on innate immune cells (Liu et al., 2004). 
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Moreover, it was demonstrated that APAP-induced liver injury was 
significantly attenuated in IFN-γ-KO mice (Ishida et al., 2002). In addition, Fas 
deficient lpr mice and FasL-deficient gld mice showed significantly decreased 
APAP-induced hepatotoxicity (Liu et al., 2004). However, Masson et al. 
demonstrated that dimethyl sulfoxide (DMSO) activated hepatic NK and NKT 
cells in vivo, which was shown by induction of intracellular levels of IFN-γ and 
granzyme B. Importantly, depletion of NK, NKT cells protected against 
APAP-induced liver injury only with DMSO as vehicle. In the absence of 
DMSO, NK, NKT cells did not induce IFN-γmRNA expression. In addition, 
there was no significant difference in liver injury between control and 
anti-NK1.1 pretreated groups after various doses of APAP in mice (Masson et 
al., 2008). Therefore, DMSO should be used cautiously in drug hepatotoxicity 
experiments. NK and NKT cells may only be involved in APAP hepatotoxicity if 
these cells are activated independently. Although it is known that APAP 
induces inflammatory gene expression in mice (Cover et al., 2006), the 
relevance of this for liver injury has not been determined.  
The production of tumor necrosis factor-α (TNF-α) is one of the 
earliest events in the hepatic inflammatory response, and TNF-α is mainly 
released by activated liver macrophages (Decker, 1990). Ishida et al. reported 
that liver injury in mice deficient in the 55 KDa TNF receptor (TNF-Rp55) was 
attenuated after APAP challenge. In addition, APAP-induced mortality was 
reduced in TNF-Rp55 KO mice (Ishida et al., 2004). Moreover, post-treatment 
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of anti-TNF-α Ab at 2 hours and 8 hours after APAP administration reduced 
hepatotoxicity significantly, which was shown by serum ALT levels (Ishida et 
al., 2004). However, a reduction in TNF-α by pre-treatment with 
anti-TNF-α antibodies did not decrease APAP-induced liver injury (Simpson et 
al., 2000; Yee et al., 2007). In addition, TNF-α and lymphotoxin-α double KO 
mice did not show any protection against APAP overdose (Boess et al., 1998). 
The reason for using these double knockout mice is that these two closely 
related cytokines may cross-compete for binding at the TNF receptors on 
target cells (Vandenabeele et al., 1995). In contrast, it was reported that 
TNF-Rp55 KO mice exaggerate APAP-induced hepatotoxicity (Gardner et al., 
2003). Therefore, further studies need to be conducted to elucidate how TNF 
signaling is involved in APAP-induced liver injury.  
It has been recently discussed whether another proinflammatory 
cytokine, IL-1, is involved in APAP-induced hepatotoxicity. There are two 
distinct types of IL-1, IL-1 α and IL-1 β, both of which signal through IL-1 
receptor (IL-1 R). IL-1β is a very potent proinflammatory cytokine, which 
requires processing by activated caspase-1 (Mariathasan et al., 2004; 
Martinon et al., 2002; Ogura et al., 2006). It is known that the combination of 
two distinct signaling pathways triggers caspase 1 activation. One is the 
activation of a cytosolic protein complex called the inflammasome. Three 
types of inflammasomes are reported based on biochemical analysis of three 
Apaf-1-like proteins, NALP1, NALP2, NALP3 (Agostini et al., 2004). The 
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NALP3 inflammasome is composed of NALP3, apoptosis-associated 
speck-like protein containing a caspase recruitment domain (ASC) which is 
the adaptor protein, and caspase 1 (Trendelenburg, 2008). The other pathway 
involves activation of immune cells, such as macrophages, via Toll-like 
receptor (TLR) agonists, which induces the synthesis of pro-IL-1-β via NF-kB 
and certain inducible components of the inflammasome (Mariathasan and 
Monack, 2007). In the APAP model, it was reported that TLR9 and the NALP3 
inflammasome play critical roles in the induction of hepatotoxicity in mice 
(Imaeda et al., 2009). In addition, C3H/HeJ mice, which have a mutated TLR4, 
showed significant reduction of APAP-induced injury compared to controls 
without changing hepatic GSH level (Yohe et al., 2006). Furthermore, IL-1 
receptor KO mice showed a dramatic reduction of APAP-induced liver injury 
and MPO activity (Chen et al., 2007). In addition, pretreatment with a 
combination of antibodies to IL-1-α, IL-1-β, and IL-1 R also decreased 
APAP-induced hepatotoxicity (Chen et al., 2007). In spite of that, the genetic 
disruption of IL-1-receptor antagonist (IL-1RA), which binds the IL-1 R at the 
same sites with similar affinity as IL-1 but fails to induce effective signaling 
(Dinarello, 1996; Dripps et al., 1991), reduced hepatotoxicity in the APAP 
model (Ishibe et al., 2009). It was reported that the reason for this protection 
was inhibition of APAP metabolism in IL-RA KO mice. These data are 
supported by the observation that IL-1 signaling suppresses CYP gene 
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transcription via activation of NF-kB (Cao et al., 1999; Riddick et al., 2004; 
Zhou et al., 2006).  
 In terms of other cytokines, it was demonstrated that APAP-induced 
hepatotoxicity is increased in IL-13 deficient mice, as well as by IL-13 
neutralizing antibody pretreatment (Yee et al., 2007). The mechanism has not 
been investigated yet, but IL-13 may have a regulatory role in modulating the 
infiltration of neutrophils into hepatocytes following APAP.  
 Previously, it was shown that IL-10 and IL-4 synergistically inhibit 
macrophage cytotoxic activity (Oswald et al., 1992). Recently, it was reported 
that IL-10/ 4 double knockout mice are highly sensitive to APAP-induced 
hepatotoxicity without disturbance of its metabolism (Bourdi et al., 2007). In 
addition, pretreatment with an IL-6 neutralizing antibody 1hour prior to APAP 
reduced liver injury in IL-10/4 KO mice (Bourdi et al., 2007), suggesting that in 
IL-10/4 KO mice, IL-6 promoted hepatotoxicity.  
Taken together, whether innate immunity is relevant for APAP-induced 
hepatotoxicity is still highly controversial, and it is necessary to do more and 
better mechanistic studies to resolve these issues. 
f) Mitochondrial outer membrane permeabilization (MOMP) and 
Mitochondrial permeability transition (MPT) 
The mitochondrial permeability transition (MPT) is characterized by 
mitochondrial swelling, and inner membrane permeabilization to solutes of 
molecular mass up to 1500 Da (Waldmeier et al., 2003).  
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MPT pore consists of cyclophilin D (CyD) in the matrix, the adenine 
nucleotide translocase (ANT) in the inner mitochondrial membrane (IM), the 
voltage-dependent anion channel (VDAC) in the outer mitochondrial 
membrane (OM) and a number of accessory proteins (Orrenius et al., 2007). 
Direct interactions have been shown for ANT and CyD, as well as between 
ANT and VDAC (Crompton, 1999; Woodfield et al., 1998).  
CyD in the matrix is thought to be involved in the regulation of MPT pore 
formation because it can interact with the immunosuppressant, cyclosporin A 
(CsA), which prevents MPT pore opening. Moreover, CyD knockout mice 
showed resistance to ischemia/reperfusion induced cardiac injury (Lim et al., 
2007) (Figure. 1.4). 
In healthy cells, the inner mitochondrial membrane (IM) is nearly 
impermeable to all ions, including protons. This allows complexes I-IV of the 
respiratory chain to build up, across the IM, the proton gradient that is 
required for ATP synthesis (Mitchell and Moyle, 1965a, b). Therefore, the 
transport of all metabolites that cross the IM is tightly regulated by highly 
selective channels and transport proteins. The ANT has been proposed to be 
a main component of the IM. The function of ANT is exchanging of ATP and 
ADP across the IM (Zamzami and Kroemer, 2001). The ANT-mediated 
exchange (antiport) of ATP and ADP across the inner mitochondrial 
membrane is a function that is essential for generation of ATP through 
oxidative phosphorylation (Klingenberg, 1980). It is reported that mitochondria 
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isolated from ANT1/ANT2 double KO hepatocytes are relatively resistant 
against Ca2+ -induced swelling, which indicates that ANT is involved in MPT 
regulation (Kokoszka et al., 2004). Interestingly, the formation of ANT pores is 
stimulated by Bax (Brenner et al., 2000; Marzo et al., 1998; Zamzami et al., 
2000) as well as reactive oxygen species (Vieira et al., 2001). 
The permeability of the OM is also regulated. It was shown that the OM 
is normally permeable to metabolites but not to proteins, which means that 
OM permeabilization results in the release of intermembrane proteins into the 
cytosol (Kroemer et al., 2007). The VDAC is the most abundant protein of the 
OM and it is known as a nonspecific pore, allowing diffusion of solutes up to 5 
kDa (Gottlieb, 2000; Zamzami and Kroemer, 2001). It was demonstrated that 
overexpression of VDAC1 induces apoptosis in a variety of cells (Zaid et al., 
2005).  
A number of accessory proteins, such as hexokinase (HK), creatine 
kinase (CK), and peripheral-type benzodiazepine receptor (PBR) have been 
identified (Figure 1.4) (Kroemer et al., 2007). HK interacts with VDAC from the 
cytosol. The interaction between HK and VDAC might cause a conformational 
change which may prevent mitochondrial breakdown during cell stress and 
injury (Mathupala et al., 2006). However, this interaction can be disrupted by 
glycogen synthase kinase-3 beta (GSK-3β)-dependent phosphorylation of 
VDAC and can be promoted by Akt, which inhibits GSK-3β (Pastorino et al., 
2005). Creatine kinase (CK) interacts with MPT pore complex from the IM 
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(Kroemer et al., 2007) and peripheral-type benzodiazepine receptor (PBR) is 
interacting with MPT pore complex from the OM (Kroemer et al., 2007). The 
exact functions of these proteins have not been identified yet (Zamzami and 
Kroemer, 2001).  
 
Figure 1.4 
Mitochondrial permeability transition pore formation.  
Modified from (Orrenius et al., 2007) Voltage-dependent anion channel 
(VDAC), Cyclophilin D (CyD), Adenine nucleotide translocase (ANT), 
Inner mitochondrial membrane (IM), Outer mitochondrial membrane 
(OM), Cyclosporin A (CsA), Hexokinase (HK), Creatine kinase (CK), 
Peripheral-type benzodiazepine receptor (PBR) 
 
MPT pore formation is regulated in many ways. 1) MPT pore is closed at 
neutral or acidic pH. Alkalinization is permissive for pore opening with a 
maximum effect at a matrix pH of ~7.3 (Zamzami and Kroemer, 2001). 2) It 
was reported that mitochondrial ROS accumulation causes MPT 
(Kowaltowski et al., 2001). Thiol groups of inner membrane proteins are 
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oxidized. This causes conformational changes, which lead to formation of a 
large non-selective pore (Kowaltowski et al., 2001). In particular, the oxidation 
of a critical residue (Cys56) of the ADP/ATP transporter leads to MPT pore 
opening in isolated mitochondria (Costantini et al., 2000). 3) An increase in 
matrix Ca2+ enhances the probability of pore opening, while matrix Mg2+ or 
Mn2+ decrease it (Zamzami and Kroemer, 2001). In terms of calcium, high 
concentrations stimulate MPT via a decreased transmembrane electrical 
potential (Hunter and Haworth, 1979; Jurkowitz et al., 1983; Vercesi, 1987; 
Zago et al., 2000). In the APAP model, it was demonstrated that 1 h 
pretreatment with calcium channel blocking agents, e.g. diltiazem, verapamil, 
and gallopamil, protected primary cultures of rat hepatocytes. In addition, it 
has been shown that verapamil prevents APAP-induced hepatotoxicity in vivo 
(Ray et al., 1993). Moreover, calcium can activate calpains, which are 
intracellular cysteine proteases that can cleave Bid and induce MPT and cell 
death. It has been shown that the specific calpain inhibitor, calpeptin, reduced 
AIF release in isolated mouse liver mitochondria (Polster et al., 2005). In 
addition, when N-CBZ-VAL-PHE methyl ester (CBZ), which is a calpain 
inhibitor, was administered 1 hour before APAP, liver injury was significantly 
reduced (Limaye et al., 2003). Furthermore, overexpression of calpastatin, 
which is an endogenous inhibitor of calpain, attenuated APAP-induced 
hepatotoxicity (Limaye et al., 2006).  
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4) Members of the Bcl-2 family have either anti-apoptotic or 
pro-apoptotic function (Ranger et al., 2001). The members are classified by 
sequence homology in four α-helical segments, which are called BH1-BH4 
(Gross et al., 1999). The highly conserved anti-apoptotic family members 
(Bcl-2, Bcl-xL, Mcl-1 and A1) contain all 4 BH domains. The pro-apoptotic 
members can be divided into 2 groups, multi-domain pro-apoptotic members 
(Bax, Bak, and Bok) and BH3 only members (Bid, Bad, Bim, Bik, Noxa and 
Puma) (Ranger et al., 2001) (Figure 1.5). It has been demonstrated that 
overexpression of the anti-apoptotic protein Bcl-2 increases the 
transmembrane electrical potential, which prevents MPT (Kowaltowski et al., 
2000). Also, it has been reported that Bcl-2 and Bax can interact directly or 
indirectly with VDAC in the OM (Shimizu et al., 1999), whereas Bcl-2, Bcl-xL, 
Bax, and Bak interact directly with ANT (Marzo et al., 1998). Therefore, it is 




Bcl-2 family of proteins. Modified from (Ronger et al. 2001)  
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Mitochondrial outer membrane permeabilization (MOMP) is also 
regulated by Bcl-2 family members (Orrenius et al., 2007) (Figure 1.6). 
Permeabilization of the OM is caused by the oligomeric form of Bax 
(Antonsson et al., 2000), which follows binding to the truncated form of the 
BH3-domain-only pro-apoptotic protein, Bid (Eskes et al., 2000). 
Anti-apoptotic proteins, such as Bcl-2 and Bcl-xL, interact with the 
pro-apoptotic proteins Bax or Bak, which prevents their oligomerization. It has 
been suggested that the ratio of Bcl-2 to Bax determines the amount of 
Bcl-2/Bax heterodimers versus Bax/Bax homodimers, which is important in 




Mitochondrial outer membrane permeabilization (MOMP) 
formation. Modified from (Orrenius et al. 2007).  
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Li, et al. showed that ROS can stimulate phosphorylation and 
ubiquitination of Bcl-2 family proteins, thereby controlling their expression (Li 
et al., 2004a). In addition, it was shown that activated c-Jun N-terminal protein 
kinase (JNK) can phosphorylate the anti-apoptotic proteins Bcl-2 and Bcl-xL 
resulting in inactivation. At the same time, JNK can phosphorylate Bax, which 
causes activation of Bax after APAP overdose (Latchoumycandane et al., 
2007).  
How does Bax recognize the proper membrane in which to insert 
itself? Several possible Bax receptors have been suggested. The first 
candidate for a mitochondrial Bax receptor was VDAC, which is also known 
as mitochondrial porin. Tsujimoto and colleagues showed that Bax enhances 
VDAC activity which regulates the mitochondrial membrane potential and the 
release of cytochrome c during apoptosis (Shimizu et al., 1999). However, 
absence of VDAC isoforms 1, 2 and 3 did not affect apoptosis signaling in 
fibroblasts isolated from VDAC 1-3 knockout mice (Baines et al., 2007). Other 
potential Bax receptors include various components of the translocase of the 
outer mitochondrial membrane (TOM complex). Tom 22 was found to interact 
with the N-terminal of Bax (Bellot et al., 2007). In addition, it was reported that 
antibodies against Tom 22 inhibit the association of truncated Bid (tBid) /Bax 
with rat liver mitochondria (Bellot et al., 2007; Cartron et al., 2008). In contrast, 
proteolytic removal of Tom22 did not prevent against tBid/Bax-induced 
cytochrome c release in yeast (Ott et al., 2007b). Another target of Bax is 
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cardiolipin, which binds to cytochrome c in the IM and limits cytochrome c 
release during apoptosis (Ott et al., 2002). However, there is very little 
cardiolipin in the OM, representing around 0.3% of the total phospholipids in 
mitochondria from rat liver (de Kroon et al., 1997). Therefore, it is not known 
yet how Bax receptors are involved in MOMP formation. 
g) Intermembrane proteins and DNA damage 
After outer mitochondrial membrane permeabilization, intermembrane 
proteins, such as EndoG, AIF, cytochrome c, Smac/Diablo, HtrA2/Omi, 
AIF,and EndoG are released (Er et al., 2006). Cytochrome c, Smac/Diablo and 
HtrA2/Omi are released into the cytosol, which is necessary for the activation 
of caspases in the mitochondrial apoptotic pathyway (Wang, 2001). Despite 
inducing cytochrome c release, APAP does not induce caspase-3 activation 
(Knight and Jaeschke, 2002; Lawson et al., 1999). Furthermore, it was shown 
that post-treatment with a pancaspase inhibitor, ZVAD-FMK 
(benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone) did not protect against 
APAP hepatotoxicity (Lawson et al., 1999). However, a subsequent report 
showed a protective effect with pre-treatment of ZVAD-FMK (El-Hassan et al., 
2003). Most likely, the solvent dimethyl sulfoxide (DMSO) used to dissolve the 
inhibitor attenuated the APAP metabolism (Jaeschke et al., 2006). Thus, DNA 
fragmentation observed after APAP overdose is independent of the 
caspase-activated DNase (CAD).  
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EndoG and AIF are involved in DNA damage after translocation from 
mitochondria to the nucleus in APAP overdose (Bajt et al., 2006). AIF is 
thought to trigger chromatin condensation and can induce large scale DNA 
fragmentation (50-300 kb) (Susin et al., 1999). EndoG and Mn2+ dependent 
endonuclease can produce oligonucleosomal DNA fragments (Li et al., 2001). 
Subsequent studies also demonstrated that EndoG catalyzes both 
high-molecular-weight DNA cleavage and oligonucleosomal DNA breakdown 
in a sequential fashion (Widlak et al., 2001). It was observed that AIF KO mice 
have reduced APAP-induced DNA fragmentation and liver injury (Jaeschke, 
2007), indicating that AIF could be a key target for protection against APAP 
hepatotoxicity. 
Another nuclease is deoxyribonuclease 1 (DNase 1). DNase 1 is a 
Ca2+/Mg2+-dependent endonuclease, which cleaves double-stranded DNA 
into 3’-OH/5’-phospho tri-and/or tetra-oligonucleotides (Napirei et al., 2005). 
DNase1 gene expression has been demonstrated in many different organs, 
including the murine liver (Napirei et al., 2004a). Extracellular DNase1 
diffuses into necrotic cells and, together with the plasminogen system, 
induces necrotic chromatin breakdown in vitro (Napirei et al., 2004b). A recent 
study showed that DNase 1 KO mice suffered less liver injury after APAP 
overdose (Napirei et al., 2006). It was concluded that DNase 1 caused some 
of the DNA damage and aggravated energy depletion via stimulation of DNA 
repair mechanisms, such as poly-adenosine diphosphate-ribose polymerase 
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(PARP) activation during APAP-induced hepatotoxicity (Jacob et al., 2007; 
Napirei et al., 2006). In addition, it was reported that excessive PARP-1 
activation leads to depletion of nicotinamide adenine dinucleotide (NAD+) and 
ATP content that causes oncotic necrosis (Charron and Bonner-Weir, 1999; 
Ha and Snyder, 1999; Szabo and Dawson, 1998; Virag and Szabo, 2002). 
These data are supported by the fact that nicotinamide supplementation also 
decreases APAP-induced hepatotoxicity (Ray et al., 2001). However, neither 
PARP-1 KO mice (Cover et al., 2005a) nor cultured hepatocytes treated with 
a PARP inhibitor (Shen et al., 1992) were protected against APAP-induced 
liver injury. Therefore PARP activation does not appear to be critical for APAP 
hepatotoxicity. However, DNase 1 may contribute to nuclear DNA damage, 
especially at later time-points.  
3) Summary 
Acetaminophen (APAP) is only used as analgesic and antipyretic agent in 
therapeutic doses (15 mg/kg, three to four times per day). However, APAP 
overdose (a single dose of 150 mg/kg) causes hepatotoxicity (Brok et al., 
2006). APAP is eliminated by sulfation and glucuronidation. A small portion of 
APAP is metabolized by cytochrome P450 isoenzymes that produce 
N-acetyl-p-benzoquinone imine (NAPQI). NAPQI is detoxified by glutathione 
(GSH), resulting in the depletion of this sulfhydryl compound. Subsequently, 
NAPQI covalently binds to cellular proteins (Nelson, 1990), including 
mitochondrial proteins. Mitochondrial proteins appear to be the most critical 
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targets of NAPQI leading to inhibition of mitochondrial respiration and causing 
oxidative stress, which eventually triggers the mitochondrial membrane 
permeability transition (MPT) (Kon et al., 2004). In addition, mitochondrial and 
nuclear DNA fragmentation is induced. These series of events results in 
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CHAPTER 2 : HYPOTHESIS AND AIMS 
Acetaminophen (APAP) is a commonly used drug for the relief of fever and 
pain. However, an overdose of APAP is hepatotoxic. The mechanisms of 
APAP-induced liver injury have been studied extensively. Based on these 
findings, three protective strategies were investigated in detail:  
Aim 1) Glutathione (GSH) and N-acetylcysteine (NAC) 
Aim 2) Metallothionein (MT) 
Aim 3) JNK inhibitor 
Aim 1 
NAC is used at very high doses both in humans and in experimental animals. 
These doses are higher than needed for the re-synthesis of hepatic GSH 
levels. However, our lab demonstrated that a moderate dose of GSH is highly 
effective in protecting against APAP toxicity. Therefore, I investigated whether 
there is a difference between the efficacy of NAC and GSH in protecting 
against APAP hepatotoxicity.  
Aim 2 
Metallothionein (MT) has been suggested to react with free radicals. 
APAP-induced hepatotoxicity studies showed a protective effect by MT. The 
modulation of APAP toxicity was independent of P450 levels and the 
metabolic activation of APAP. In contrast, the protection appeared to be 
correlated with the antioxidant function of MT. However, it remains unclear 
whether MT can actually scavenge reactive oxygen species (ROS) of APAP. 
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Thus, the objective of this study was to investigate the mechanism by which 
induction of MT expression protects against APAP-induced hepatotoxicity in 
vivo.  
Aim3 
C-jun N-terminal kinase (JNK) has been suggested to contribute to 
APAP-induced liver injury. The postulated mechanism of JNK involvement 
was the promotion of mitochondrial Bax translocation, which triggers 
mitochondrial outer membrane pore formation resulting in the release of 
intermembrane proteins such as apoptosis inducing factor (AIF) and 
endonuclease G (EndoG). However, our laboratory reported that 
Bax-deficient mice were only temporally protected against APAP-induced liver 
injury (Bajt et al., 2008). In contrast, the protective effect of JNK inhibitor was 
observed consistently up to 12 h. Therefore, additional mechanisms of injury 
need to be triggered by JNK activation, and tested the hypothesis that JNK 
promotes iNOS induction and mitochondrial oxidant stress.  
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CHAPTER 3: MATERIALS AND METHODS 
3.1 Common methods 
3.1.1 Experimental Protocols. 
At selected times after APAP treatment, groups of animals were killed 
by cervical dislocation under isoflurane anesthesia. Blood was drawn from the 
vena cava into heparinized syringes and centrifuged. The plasma was used 
for determination of alanine aminotransferase (ALT) activities. Immediately 
after collecting the blood, the livers were excised and rinsed in saline. A small 
section from each liver was placed in 10% phosphate buffered formalin. The 
remaining liver was frozen in liquid nitrogen and stored at -80°C. 
 3.1.2. ALT.   
Plasma ALT activities were determined with the kinetic test kit 68-B 
(Biotron Diagnostics, Inc., Hernet, CA) and expressed as IU/liter.  
3.1.3 Subcellular fraction and protein concentrations.  
The method is described in the manufacturer’s instructions (Pierce, 
Rockford, IL). Mitochondria and cytosol were isolated using the mitochondria 
isolation kit for tissue (Pierce, Rockford, IL).  
Protein in cytosol and mitochondria fraction was measured using the 
bicinchoninic acid kit (Pierce, Rockford, IL).  
 
3.1.4 Western blotting. 
 Liver tissue was homogenized in 25 mM HEPES 
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(4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) (pH 7.5) containing 5 
mM EDTA, 2 mM DTT (dithiothreitol), 0.1% CHAPS 
(3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate), 1 mg/ml 
pepstatin, leupeptin, and aprotinin. Homogenates were centrifuged at 14,000  
g at 4°C for 20 min. Cytosolic extracts (10 µg per lane) were resolved by 
4–20% SDS–polyacrylamide gel electrophoresis under reducing conditions. 
Separated proteins were transferred to polyvinylidine difluoride membranes 
(PVDF, Immobilin-P, Millipore, Bedford, MA). For metallothionein, separated 
proteins were transferred to a polyvinylidine difluoride membrane (PVDF, 
Immobilon-PSQ Millipore, Bedford, MA), which is a special membrane for 
smaller molecular weight proteins. The membranes were first blocked with 
5% milk in TBS (20 mM Tris, 154 mM NaCl, 0.1% Tween 20, and 0.1% BSA) 
overnight at 4°C, followed by incubation with primar y antibody, e.g., a rabbit 
anti-Bax polyclonal antibody (Cell signaling Technology, Danvers, MA), a 
rabbit anti-AIF monoclonal antibody (Epitomics, Burlingame, CA), rabbit 
anti-Cytochrome c polyclonal antibody (Santa Cruz Biotechnology, Santa 
Cruz, CA), a monoclonal mouse anti-Metallothionein antibody (DAKO Corp., 
Carpinteria, CA) for 2 h at room temperature. The membranes were washed 
and then incubated with the secondary antibody with horseradish peroxidase 
(Santa Cruz Biotechnology). Proteins were visualized by enhanced 
chemiluminescence (Amersham Pharmacia Biotech. Inc., Piscataway, NJ), 
according to the manufacturer’s instructions. Densitometric analysis of the 
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gels was performed with a GS170 Calibrated Imaging Densitometer (Biorad, 
Hercules, CA) using Quantity One 4.0.3 software (Biorad).  
 
3.1.5 Total GSH and GSSG measurements. 
Total soluble GSH and GSSG were measured in the liver homogenate 
and in isolated mitochondria with a modified method of Tietze as described 
(Jaeschke and Mitchell, 1990; Knight et al., 2002). Frozen tissues (or isolated 
mitochondria) were homogenized at 0° C in 3% sulfosal icylic acid containing 
0.1 mM EDTA (Jaeschke and Mitchell, 1990). An aliquot of the homogenate 
was added to 10 mM N-ethylmaleimide (NEM) in potassium phosphate buffer 
(KPP), and another aliquot was added to 0.01 N HCl. The NEM-KPP sample 
was centrifuged, and the supernatant was passed through a C18 cartridge to 
remove free NEM and NEM-GSH adducts (Sep-Pak; Waters, Milford, MA). 
The HCl sample was centrifuged, and the supernatant was diluted with KPP. 
All samples were assayed using dithionitrobenzoic acid (DTNB). All data are 
expressed in GSH-equivalents.   
3.1.6 Histology, TUNEL assay, immunohistochemistry for nitrotyrosine. 
Formalin-fixed tissue samples were embedded in paraffin and 5 µm 
sections were cut. Replicate sections were stained with hematoxylin and 
eosin (H&E) for evaluation of necrosis (Gujral et al., 2002). For the terminal 
deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) 
assay, sections of liver were stained with the In Situ Cell Death Detection Kit, 
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AP (Roche Diagnostics, Indianapolis, IN) as described in the manufacturer’s 
instructions (Gujral et al., 2002). Nitrotyrosine protein adducts were detected 
with standard immunohistochemical methods using an anti-nitrotyrosine 
antibody (Molecular Probes, Eugene, OR) (Knight et al., 2002).  
3.1.7 Quantitative real-time polymerase chain reaction (qRT-PCR).  
Total RNA was reversed transcribed with M-MLV reverse 
transcriptase (Invitrogen, Carlsbad, CA) and oligo-dT primers (ABI Primer 
Express software, Foster City, CA).  
The primer sequences for the genes examined are as follows:  
β-actin: 
Forward, 5’-GTATGACTCCACTCACGGCAAA-3’, 
Reverse, 5’-GGTCTCGCTCCTGGAAGATG-3’,  
MT-1:  
Forward 5’-AATGTGCCCAGGGCTGTGT-3’, 
Reverse, 5’-GCTGGGTTGGTCCGATACTATT,  
MT-2:  
Forward, CCTCACTGGCAGGAAATCATC,  
Reverse, 5’-CCTCGTGGAGACGCTTTACATA,  
iNOS:  
Forward, 5’-ACATCAGGTCGGCCATCACT3’,  
Reverse, 5’-CGTACCGGATGAGCTGTGAATT-3’.  
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The SYBR green PCR Master Mix (Applied Biosystems, Foster City, CA) was 
used for real-time PCR analysis. The relative differences in gene expression 
between groups were expressed using cycle time (Ct) values. Ct values for 
the various genes were first normalized with that of β-actin in the same 
sample, and then relative differences between groups were expressed as 
relative increases setting control as 1. 
3.1.8 Statistics.  
Data are expressed as means ± S.E. Comparison between two 
groups were performed with Student’s t-test or one-way ANOVA followed by 
Bonferroni t-test for multiple groups. If the data were not normally distributed, 
the Mann-Whitney test was applied for comparison of two groups and the 
Kruskal-Wallis Test (nonparametric ANOVA) followed by Dunn’s Multiple 
Comparisons Test for multiple groups. P<0.05 was considered significant. 
 
3.2 Specific methods for Aim 1 
3.2.1 Animals. 
Male C3HeB/FeJ mice (8-10 weeks old) were purchased from 
Jackson Laboratories (Bar Harbor, ME). Animals received humane care 
according to the criteria outlined in the “Guide for the Care and Use of 
Laboratory Animals”. The experimental protocol was approved by the 
Institutional Animal Care and Use Committee of Kansas University Medical 
Center. The animals were fasted overnight and then received 300 mg/kg 
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APAP (Sigma Chemical Co., St. Louis, MO) dissolved in warm saline (15 
mg/ml) (i.p.). Some animals received a single intravenous bolus dose of 
glutathione (200 mg/kg GSH; 0.65 mmol/kg) dissolved in phosphate-buffered 
saline (PBS), 106 mg/kg (0.65 mmol/kg) or 318 mg/kg (1.95 mmol/kg) 
N-acetyl cysteine, a mixture of 3 amino acids [49 mg/kg (0.65 mmol/kg) 
glycine, 96.4 mg/kg (0.65 mmol/kg) glutamic acid, and 106 mg/kg (0.65 
mmol/kg) NAC] or a mixture of 2 amino acids [73.5 mg/kg (0.98 mmol/kg) 
glycine and 144.6 mg/kg (0.98 mmol/kg) glutamic acid]. All compounds were 
administered intravenously through the penile vein 1.5 h after APAP injection 
(Bajt et al., 2003; Cover et al., 2005b; Knight et al., 2002). The rationale for 
the treatment at 1.5 h is based on the assumption that by that time most of the 
administered APAP has been metabolized and most of the protein binding of 
NAPQI is completed. 
3.2.2 NMR experiments.  
For NMR experiments, further groups of mice were treated with APAP 
and the study substances at t = 1.5 h as mentioned above [GSH, NAC, a 
mixture of 3 amino acids (glycine, glutamate, cysteine), a mixture of 2 amino 
acids, or cysteine]. At t = 1.5 h or t = 6 h, all mice received [U-13C]glucose 
(500 mg/kg; 2.78 mmol/kg) (Cambridge Isotopes, Andover, MA), which was 
injected intraperitoneally in bolus to study metabolic changes in awake mice. 
Using 500 mg/kg [U-13C]glucose, plasma glucose was <10 mM in all 
experiments. The mice were killed by cervical dislocation and the livers 
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freeze-clamped immediately. Blood was taken after severing of the carotid 
artery and put into tubes containing heparin. Water-soluble metabolites were 
extracted from blood or tissue with perchloric acid and analyzed by NMR 
spectroscopy (Zwingmann and Bilodeau 2006). 
 
3.3 Specific methods for Aim 2 
3.3.1 Animals. 
Male C57BL/6J mice (8-10 weeks old), male age-matched wildtype 
129S1/SvImJ and male MT-1/MT-2 deficient mice 
(129S7/SvEvBrd-Mt1tm1Bri Mt2tm1Bri/J) were purchased from Jackson 
Laboratories (Bar Harbor, ME). Animals received humane care according to 
the criteria outlined in the “Guide for the Care and Use of Laboratory Animals”. 
The experimental protocol was approved by the Institutional Animal Care and 
Use Committee of Kansas University Medical Center. Some animals received 
a non-toxic dose of 100 µmol/kg zinc chloride (Fluka Chemical Corp., 
Milwaukee, WI) dissolved in saline (9.9 µmol/ml) subcutaneously once a day 
for 3 days (Liu et al., 2009). All animals were fasted overnight and on the 4th 
day, they received 300 mg/kg APAP (Sigma Chemical Co., St. Louis, MO) 
dissolved in warm saline (15 mg/ml) by intraperitoneal injection.  
3.3.2 Mouse hepatocyte isolation. 
Primary hepatocytes were isolated from overnight fasted mice with a 
standard collagenase procedure as previously described in detail (Bajt et al., 
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2004). Untreated and ZnCl2-treated animals were used. Some of the animals 
were treated with 100 mg/kg phorone i.p. (Sigma) to deplete hepatic GSH 
levels 90 min before cell isolation. The GSH-depleted cells were then 
incubated in the presence of the GSH synthesis inhibitor buthionine 
sulfoximine (1 mM) (Sigma). From the isolation of one mouse liver, a typical 
yield was about 50–60 x106 hepatocytes. Cell viability, as determined by 
trypan blue exclusion, was generally >90%, and cell purity was >95% 
hepatocytes. Cells were plated in six-well plates (6 x 105 cells/well) (Biocoat 
collagen I cellware plates; Becton Dickinson) in Williams’ Medium E (Gibco) 
containing 10% fetal bovine serum (Gibco), 100 U/ml penicillin/streptomycin, 
and 1 x 10-7 M insulin and cultured at 37 °C in room air with 5%  CO2. After an 
initial 4 h attachment period, cultures were washed with phosphate-buffered 
saline (PBS) and then plain culture medium (controls) or media containing 
various concentrations of hydrogen peroxide were added. Cell injury was 
assessed by lactate dehydrogenase (LDH) release into the medium. LDH 
activities were measured as described (Bajt et al., 2004).  
3.3.3 Analysis of MT-NAPQI interactions by mass spectrometry.  
MT from rabbit liver was purchased from Sigma (M5269) as a 
lyophilized powder. The protein was suspended in deionized water to a 
protein concentration of 1 mg/ml. NAPQI was purchased from Sigma (A7300) 
and diluted in water to a final concentration of 12 µg/ml. For mass 
spectrometric measurements, protein samples were desalted on a C18 
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reverse phase column (Zorbax C18SB Wide pore guard Column, MicroTech 
Scientific, 1 cm x 0.32 mm), which was connected online to a valve to direct 
the flow either to waste or to the mass spectrometer (MS). After washing the 
column with 0.1% (v/v) TFA at a flow of 100 µl/min, the flow was directed to 
the mass spectrometer and the protein eluted using a 0-60% (v/v) acetonitrile 
gradient in 0.1% TFA at a flow rate of 20 µl/min. Electrospray ionization (ESI) 
MS data were acquired in the m/z range 800-2000 on a ThermoFinnigan LTQ 
FT. The mass spectrometer was under manual control to facilitate switching 
between two modes of data acquisition, on the Ion Trap (IT) and on the Ion 
Cyclotron Resonance Fourier Transform cell (ICR FT). Final optimized 
settings for detection of MT were: ion spray voltage 2.1 kV, capillary 
temperature 250 °C, capillary voltage 34V. The two modes of operation have 
different sensitivity and mass resolution. The charge state of all protein 
species detected was calculated from the isotopic distribution of the high 
resolution spectrum obtained in the ICR FT. However, due to the higher 
sensitivity of the IT, data reported here are for the acquisition on the IT. 
Masses of the different protein variants were calculated from the multiple 
charged protein ions using the deconvolution software included in 
BioworksBrowser V. 3.1 (ThermoFinningan). The resulting masses were 




3.4 Specific methods for Aim 3 
3.4.1 Animals. 
Male C57BL/6J mice (8-10 weeks old), JNK2-deficient mice 
(B6.129S2-Mapl9tm1Flv/J or age-matched wild type (C57Bl/6J) mice were 
purchased from Jackson Laboratories (Bar Harbor, ME). Animals received 
humane care according to the criteria outlined in the “Guide for the Care and 
Use of Laboratory Animals”. The experimental protocol was approved by the 
Institutional Animal Care and Use Committee of the Kansas University 
Medical Center.  
3.4.2 Experimental Protocols. 
All animals were fasted overnight and some animals received a JNK 
inhibitor, 10 mg/kg SP600125 (LC Laboratories) dissolved in 8.3 % DMSO in 
PBS (1 mg in 125 µl of DMSO diluted with 1375 µl of PBS) (Hanawa et al., 
2008). JNK inhibitor and DMSO, unless noted otherwise, were injected 
intraperitoneally 1 h prior to 600 mg/kg APAP injection (Sigma Chemical Co., 
St. Louis, MO). Some animals received 300 mg/kg APAP with either 0.65 
mmol/ kg GSH (i.v.) administration at 1.5h after APAP or 100 µmol/kg ZnCl2 
administration for 3 days. APAP was dissolved in warm saline (15 mg/ml). 
Some animals received 2 mg/kg ip lipopolysaccharide (Sigma), with/without 
3.3 mg/kg ip L-N-(1-iminoethyl)lysine (L-Nil) (Cayman) at 0 and 3 h.  
3.4.3 Measurement of Nitrite/nitrate in plasma. 
The plasma concentrations of nitrite/nitrate were determined with a kit 
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(Cayman) by means of the Griess reaction. 
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CHAPTER 4: NOVEL MECHANISMS OF PROTECTION AGAINST 
ACETAMINOPHEN HEPATOTOXICITY IN MICE BY 
GLUTATHIONE AND N-ACETYLCYSTEINE 
 
4.1 Abstract. 
Acetaminophen (APAP) overdose is a major cause of acute liver 
failure. The glutathione (GSH) precursor N-acetylcysteine (NAC) is used to 
treat patients with APAP overdose for up to 48 h. Although it is well 
established that early treatment with NAC can improve the scavenging of the 
reactive metabolite N-acetyl-p-benzoquinone imine (NAPQI), protective 
mechanisms at later times remain unclear. To address this issue, fasted 
C3Heb/FeJ mice were treated with 300 mg/kg APAP and then received 
intravenously 0.65 mmol/kg GSH or NAC at 1.5 h after APAP. The animals 
were sacrificed at 6 h. APAP alone caused severe liver injury with 
peroxynitrite formation and DNA fragmentation, all of which were attenuated 
by both treatments. However, GSH (-82%) was more effective than NAC 
(-46%) in preventing liver injury. Using nuclear magnetic resonance 
spectroscopy to measure tissue ATP levels and the substrate flux through the 
mitochondrial Krebs cycle, it was observed that the reduced liver injury 
correlated with accelerated recovery of mitochondrial GSH content, 
maintenance of ATP levels and an increased substrate supply for the 
mitochondrial Krebs cycle compared to APAP alone. NAC treatment was less 
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effective in recovering ATP and mitochondrial GSH levels and showed 
reduced substrate flux through the Krebs cycle, compared to GSH. However, 
increasing the dose of NAC improved the protective effect similar to GSH 
suggesting that the amino acids not used for GSH synthesis were used as 
mitochondrial energy substrates. Taken together, delayed treatment with GSH 
and NAC protect against APAP overdose by dual mechanisms, i.e. by 
enhancing hepatic and mitochondrial GSH levels (scavenging of reactive 




Acetaminophen (APAP) is a safe analgesic at therapeutic levels. 
However, an overdose can cause severe liver injury and even acute liver 
failure. During the last decade, APAP became the most frequent cause of 
acute liver failure in the US and many other countries (Larson et al., 2005). 
Early animal studies established the formation of the reactive metabolite 
N-acetyl-p-benzoquinone imine (NAPQI), which first depletes glutathione and 
subsequently binds to proteins, critical events in APAP toxicity (Jollow et al., 
1973; Mitchell et al., 1973a; Mitchell et al., 1973b). Based on this mechanistic 
insight, N-acetylcysteine (NAC) was introduced to treat patients with APAP 
overdose in the 1970s (Prescott et al., 1977). Even today, NAC therapy is still 
the best therapeutic option for the overdosed patient (Polson and Lee, 2005). 
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NAC is most effective when given as early as possible after APAP intoxication. 
The main mechanism of action of NAC is to promote hepatic GSH synthesis 
(Corcoran and Wong, 1986; Lauterburg et al., 1983), which supports the 
detoxification of NAPQI and reduces protein binding (Corcoran et al., 1985).  
However, NAC therapy is clinically effective even when initiated 24 h after 
APAP overdosing, i.e. at a time when there is no relevant amount of drug left 
to be metabolized (Harrison et al., 1990; Smilkstein et al., 1988). These 
observations suggest that there might be other, yet unknown mechanisms of 
protection. This hypothesis is also supported by the fact that NAC can protect 
in models without GSH depletion (Zwingmann and Bilodeau, 2006). Recent 
insight into the molecular mechanisms of APAP-induced hepatotoxicity in a 
mouse model indicated that the early protein binding is an essential initiating 
event, which requires intracellular propagation and amplification (Jaeschke 
and Bajt, 2006; Jaeschke et al., 2003). Key to this propagation mechanism is 
mitochondrial dysfunction and oxidant stress (Jaeschke and Bajt, 2006). 
Intravenous administration of GSH after APAP treatment resulted in the 
accelerated recovery of GSH in the mitochondria (Knight and Jaeschke, 
2002). The elevated levels of mitochondrial GSH effectively scavenged 
reactive oxygen and peroxynitrite, which reduced APAP-induced liver injury 
and promoted regeneration (Bajt et al., 2003; Cover et al., 2005b; Knight and 
Jaeschke, 2002). Delayed treatment with NAC had a similar protective effect 
(James et al., 2003c). These findings support the hypothesis that the delayed 
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supply of cysteine can be involved in a second mechanism of protection, i.e. 
the scavenging of reactive oxygen species and peroxynitrite (Jaeschke and 
Bajt, 2006; Jaeschke et al., 2003). The dose of GSH we used in our recent 
experiments (Bajt et al., 2003; Cover et al., 2005b; Knight and Jaeschke, 
2002) was based on previous data showing its efficacy in supporting the 
recovery of hepatic GSH levels after starvation (Wendel and Jaeschke, 1982). 
This dose provides enough cysteine to re-synthesize twice the entire GSH 
content of a mouse liver. However, in most studies with NAC, generally much 
higher doses are used, e.g. 300 – 1200 mg/kg of NAC (Corcoran et al., 1985; 
James et al., 2003c; McConnachie et al., 2007; Salminen et al., 1998; 
Whitehouse et al., 1985), which is sufficient to synthesize the hepatic GSH 
content between 6 and 23 times. For treatment of acute APAP poisoning in 
patients, the recommended dose for NAC is a 150 mg/kg loading dose 
followed by maintenance doses of 50 mg/kg every 4 h (Polson and Lee, 
2005). Again, even the loading dose alone would be sufficient cysteine to 
synthesize several times the entire hepatic GSH content. This raises the 
question whether GSH is more effective than NAC, or if there are additional 
benefits of high doses of NAC that have not been considered. To address this 
important question, we compared the efficacy and mechanisms of protection 





GSH treatment was most effective in preventing APAP-induced liver 
injury. Male C3Heb/FeJ mice treated with an overdose of APAP (300 mg/kg) 
showed evidence of severe liver injury at 6 h as indicated by increases in 
plasma ALT values (Figure 4.1.A). In addition, there was only a partial 
recovery of the hepatic GSH content and evidence of oxidant stress, as 
indicated by the elevated levels of hepatic GSSG and increased 
GSSG-to-GSH ratio (Figure 4.1 B-D). Treatment of mice with equimolar doses 
of GSH or NAC (0.65 mmol/kg) at 1.5 h after APAP resulted in reduced 
increases in plasma ALT. (Figure 4.1 A). However, GSH treatment was more 
effective in preventing APAP-induced liver injury as indicated by the 82% 
lower ALT values compared to the 46% reduction with NAC. However, both 
treatments resulted in a complete recovery of hepatic GSH levels (Figure 4.1 
B). The hepatic GSSG content was further increased in the GSH and NAC 
treated mice, compared to APAP alone. However, the GSSG-to-GSH ratio 
was similar in all APAP-treated groups (Figure 4.1 D). These results suggest 
that ROS are still being formed after GSH or NAC treatment but this oxidant 
stress is more efficiently detoxified due to the higher GSH levels. The 
biochemical data was confirmed by histological findings. H&E staining of liver 
sections indicated the substantial centrilobular necrosis 6 h after APAP 
administration (Figure 4.2). The loss of basophilic staining, vacuolization, cell 
swelling and karyolysis around the centrilobular veins documents that the 
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cells undergoing oncotic necrosis (Figure 4.7). The extent of necrosis 
correlated with massive DNA fragmentation, as demonstrated by the TUNEL 
assay and peroxynitrite formation, as indicated by the presence of 
nitrotyrosine protein adducts in the centrilobular areas (Figure 4.2). Delayed 
treatment with GSH markedly reduced the area of necrosis, nitrotyrosine 
protein adducts as well as the number of TUNEL-positive cells (Figure 4.2; 
Figure 4.7). Treatment with NAC also attenuated the areas of necrosis, 
nitrotyrosine staining and the extent of DNA damage (Figure 4.2). However, 
the protective effect of NAC was less pronounced compared than GSH. 
Together, these results suggest that treatment with GSH 1.5 h after APAP 
administration was more effective in protecting the liver compared to an 
equimolar dose of NAC. Because hepatic GSSG levels further increased after 
GSH or NAC treatment compared to APAP alone, this indicates that ROS are 
more effectively detoxified but are still being formed. Thus, both delayed 
treatments did not affect the oxidant stress induced by APAP overdose 
(Figure 4.1C,D).  
GSH and NAC treatment had similar effects on early GSH recovery.  
Although there was a clear difference in tissue injury between the GSH- and 
the NAC-treated groups, based on the GSH and GSSG data of the 6 h time 
point (Figure 4.1), it appears that the efficacy in supplying cysteine for 
recovery of hepatic GSH levels and scavenging reactive oxygen was similar 
between the 2 treatment groups. To verify that this conclusion is justified, a 
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more detailed time course of the depletion and recovery of hepatic GSH 
levels was studied (Figure 4.3 A). Treatment with APAP resulted in an 86% 
depletion of hepatic GSH levels within 30 min and no further decline 
thereafter (Figure 4.3 A). When saline was injected 1.5 h after APAP, there 
was no immediate recovery of the GSH content. However, between 2.5 and 4 
h, GSH levels spontaneously recovered to about 70% of baseline, with no 
further improvement thereafter (Figure 4.3 A). In contrast, injection of GSH or 
NAC resulted in a rapid and complete recovery of hepatic GSH levels within 1 
h and an additional increase over the next 1.5 h (Figure 4.3 A). Despite the 
similar recovery of the hepatic GSH content, plasma ALT values indicated 
improved protection in the GSH-treated animals compared to NAC (Figure 4.3 
B). Because our previous studies identified the mitochondria as the main 
source of oxidant stress and peroxynitrite formation (Cover et al., 2005b; 
Jaeschke, 1990; Knight et al., 2001; Tirmenstein and Nelson, 1990), the 
mitochondrial GSH content was evaluated 45 min after the injection of GSH or 
NAC (Figure 4.3 C). Compared to an untreated control, mitochondrial GSH 
levels are still 90% depleted 2.25 h after APAP exposure. Injection of GSH 
resulted in a complete recovery of mitochondrial GSH levels (Figure 4.3 C). 
However, injection of an equimolar dose of NAC caused only a partial 
recovery of the mitochondrial GSH content to levels 34% below controls or 
GSH-treated animals (Figure 4.3 C). These results indicate that the supply of 
cysteine through GSH or NAC is sufficient to re-synthesize GSH in the cytosol 
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but there is a delay of the energy-dependent transport of GSH into the 
mitochondria with NAC. 
Hepatic energy status and metabolism.  
It is well established that APAP-induced hepatotoxicity causes mitochondrial 
dysfunction with depletion of hepatic ATP levels (Jaeschke, 1990; Kon et al., 
2004; Tirmenstein and Nelson, 1990). In addition, it was recently shown that 
high levels of NAC can improve mitochondrial energy metabolism 
(Zwingmann and Bilodeau, 2006). Therefore, we hypothesized that the 
difference between GSH and NAC treatment might be caused by differential 
effects on mitochondrial energy metabolism. Using NMR, we compared 
changes in ATP levels with alterations in mitochondrial energy metabolism. 
We chose to evaluate these parameters at two time points, an early time (2.25 
h) during the initiation of the injury and a late time (6.75 h) when substantial 
necrosis was evident. As a measure of the hepatocellular energy state, the 
concentrations of ATP were determined from 31P-NMR spectra of liver 
extracts (Figure 4.4). ATP levels in the livers of mice treated with APAP were 
reduced to 66% and 42% of saline-treated controls at the early and late time 
point, respectively. Whereas ATP levels were not significantly different from 
controls after administration of GSH at both time-points, treatment with NAC 
did not result in an early ATP recovery, and improved the energy status only 
partially (to 70% of controls) at the late time point.   
GSH causes early and late upregulation of mitochondrial energy 
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metabolism.  
Two pathways mediate the entry of carbon from [U-13C]glucose into the Krebs 
cycle after conversion to [U-13C]pyruvate (Figure 4.5 A): 1) Pyruvate 
dehydrogenase (PDH), which converts pyruvate into acetyl-CoA and is 
considered the key enzyme for mitochondrial energy metabolism. 2) Pyruvate 
carboxylase (PC) converts pyruvate into the Krebs cycle intermediate 
oxaloacetate, which needs to combine with acetyl-CoA to allow for synthesis 
of amino acids such as glutamate. Oxaloacetate can also be replenished after 
anaplerotic entry of other substrates to the Krebs cycle, such as the glutamate 
residue in GSH. Therefore, we administered GSH or NAC together with 
[U-13C]glucose 1.5 h after APAP treatment. Additional GSH/NAC treated 
animals were injected with [U-13C]glucose at 6 h. Figure 4.5 shows the 
amounts of 13C-labelled glutamate (C-4 position), formed through PDH from 
[U-13C]glucose (Figure 4.5 D,E), as well as of the Krebs cycle intermediate 
succinate (Figure 4.5 B,C). Despite ATP depletion, treatment of mice with 
APAP did not result in a diminished flux through PDH with reduced succinate 
or glutamate formation at both time points (Figure 4.5 B-E). However, 
administration of GSH to APAP-treated mice caused a significantly 
augmented formation of both 13C-labelled glutamate and succinate (more 
than 4-fold and 2-fold elevation at 2.25 h, respectively), which supports early 
mitochondrial ATP formation (Figure 4.5 B,D). The stimulating effects on 
glutamate and succinate formation could still be observed 6.75 h after APAP 
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administration (Figure 4.5 C,E). The effects of NAC were much less 
pronounced compared to GSH at 2.25 h (Figure 4.5 B,D) and disappeared at 
6.75 h (Figure 4.5 C,E). 
High doses of NAC effectively protect against APAP hepatotoxicity.  
To evaluate if the difference between GSH and NAC in protecting against 
APAP toxicity is caused by the different amount of amino acids administered, 
3 times higher doses of NAC were injected and the efficacy compared to the 3 
individual amino acids of GSH (glutamate, glycine and cysteine) and to a 
similar dose of only 2 amino acids (glutamate, glycine). Both, the high dose of 
NAC and the 3 amino acids were more effective than the low NAC group in 
protecting against APAP-induced toxicity (Figure 4.6 A) and in maintaining 
liver ATP levels at early and later time points (Figure 4.6 C,D). All three 
treatments were equally effective in restoring total hepatic GSH levels (Figure 
4.6 B). In contrast, treatment with 2 amino acids (lack of cysteine) did not 
improve the recovery of hepatic GSH levels and failed to protect despite the 
partial improvement of hepatic ATP levels (Figure 4.6 A-D). The substrate flux 
through the Krebs cycle correlated with ATP formation in the different 

















Plasma alanine aminotransferase (ALT) activities (A) and the hepatic content 
of glutathione (GSH+GSSG) (B) and glutathione disulfide (GSSG) (C) were 
quantified in control animals or mice treated with 300 mg/kg acetaminophen 
(APAP) for 6 h. The ratio between GSSG and total glutathione was calculated 
(D). Some of the animals received additionally 10 ml/kg saline, 0.65 mmol/kg 
GSH or 0.65 mmol/kg N-acetylcysteine (NAC) iv 1.5 h after APAP. Data 
represent means ± SE of n = 5 animals per group. *P<0.05 (compared to 









Histological assessment of liver injury (hematoxilin & eosin, H&E), 
peroxynitrite formation (nitrotyrosine staining) and DNA fragmentation 
(TUNEL assay) in control animals or mice treated with 300 mg/kg 
acetaminophen (APAP) for 6 h. Some of the animals received additionally 10 
ml/kg saline, 0.65 mmol/kg GSH or 0.65 mmol/kg N-acetylcysteine (NAC) iv 
1.5 h after APAP. The representative pictures show extensive centrilobular 
necrosis, which correlated with the areas of nitrotyrosine staining and 
TUNEL-positive cells in APAP-treated animals. Both, GSH and NAC 
treatment improved all parameters with GSH being more effective than NAC. 














Time course of hepatic glutathione (GSH+GSSG) levels (A) and plasma ALT 
activities (B) after treatment with 300 mg/kg APAP. Some animals received 
additionally 10 ml/kg saline, 0.65 mmol/kg GSH or 0.65 mmol/kg 
N-acetylcysteine (NAC) iv 1.5 h after APAP. Data represent means ± SE of n = 
4 animals per time point. *P<0.05 (compared to APAP/saline); #P<0.05 
(compared to APAP/GSH). Mitochondrial glutathione content in controls or 2.5 
h after injection of APAP alone or in combination with GSH and NAC (C). Data 
represent means ± SE of n = 4 animals per group or time point. *P<0.05 





















Tissue concentrations of ATP (µmol/g wet weight), as calculated from its 
resonances in 31P-NMR spectra of liver extracts. The mice were treated with 
300 mg/kg APAP and some subsequently received 0.65 mmol/kg GSH or 
NAC at 1.5 h after APAP. ATP levels were measured 2.25 h (A) or 6.75 h (B) 
after treatment with APAP. Data represent means ± SE of n = 4 animals per 





















Labeling of glutamate from [U-13C]glucose. [U-13C]glucose is first 
metabolized to [3-13C]pyruvate, which is converted via pyruvate 
dehydrogenase (PDH) and pyruvate carboxylase (PC) to [2-13C]acetyl-CoA 
and [3-13C]oxaloacetate, respectively. The fluxes through PDH and PC lead to 
a different 13C-labeling pattern in the Krebs cycle intermediate citrate, and are 
finally measured by the isotopomer pattern of glutamate in 13C-NMR spectra 
(A). Concentrations of 13C-labelled [4,5-13C]glutamate and the Krebs cycle 
intermediate [2,3-13C]succinate (nmol/g wet weight), as calculated from their 
resonances in 1H- and 13C-NMR spectra of liver extracts. The mice were 
treated with 300 mg/kg APAP and some subsequently received 0.65 mmol/kg 
GSH or NAC at 1.5 h after APAP. Glutamate (D,E) and succinate (B,C) levels 
were measured 45 min after injection of [U-13C]glucose, i.e. at 2.25 h after 
APAP (B,D) or 45 min after injection of [U-13C]glucose , i.e. 6.75 h after APAP 
(C,E). Data represent means ± SE of n = 4 animals per group. *P<0.05 












Plasma alanine aminotransferase (ALT) activities (A) and the hepatic content 
of glutathione (GSH+GSSG) (B) were measured in mice treated with 300 
mg/kg acetaminophen (APAP) for 6 h. Some of the animals received 
additionally 10 ml/kg saline, 0.65 mmol/kg N-acetylcysteine (l-NAC), 1.95 
mmol/kg NAC (h-NAC), a mixture of 3 amino acids (0.65 mmol/kg of glycine, 
glutamic acid and NAC) (3AS) or a mixture of 2 amino acids (0.98 mmol/kg 
glycine and glutamic acid) (2AS) iv 1.5 h after APAP. Data represent means ± 
SE of n = 5 animals per group. *P<0.05 (compared to controls); #P<0.05 
(compared to APAP/saline). Tissue concentrations of ATP (µmol/g wet weight) 
(C, D), as calculated from its resonances in 31P-NMR spectra of liver extracts. 
The mice were treated as under A-B and ATP levels were measured 2.25 h 
(C) or 6.75 h (D) after treatment with APAP. Data represent means ± SE of n = 








Histological assessment of liver injury (hematoxilin & eosin, H&E) in control 
animals or mice treated with 300 mg/kg acetaminophen (APAP) for 6 h. Some 
of the animals received additionally 10 ml/kg saline, 0.65 mmol/kg GSH or 
0.65 mmol/kg Nacetylcysteine (NAC) iv 1.5 h after APAP. The representative 
pictures show extensive centrilobular necrosis as indicated by the loss of 
basophilic staining, vacuolization, cell swelling and karyolysis in APAP-treated 
animals. Both, GSH and NAC treatment improved the area of necrosis with 



















Concentrations of 13C-labelled [4,5-13C]glutamate and the Krebs cycle 
intermediate [2,3-13C]succinate (nmol/g wet weight), as calculated from their 
resonances in 1H- and 13CNMR spectra of liver extracts. The mice were 
treated with 300 mg/kg APAP and some subsequently received additionally 
10 ml/kg saline, 0.65 mmol/kg N-acetylcysteine (l-NAC), 1.95 mmol/kg NAC 
(h-NAC), a mixture of 3 amino acids (0.65 mmol/kg of glycine, glutamic acid 
and NAC) (3AS) or a mixture of 2 amino acids (0.98 mmol/kg glycine and 
glutamic acid) (2AS) iv 1.5 h after APAP. Data represent means ± SE of n =5 











The objectives of this investigation were to evaluate whether there is 
a difference in the efficacy to protect against APAP hepatotoxicity between 
GSH and clinically relevant doses of NAC, and to assess the mechanisms of 
this protection. The present data indicate that when animals are treated with 
low equimolar doses of GSH or NAC, GSH is more effective due to the higher 
amounts of amino acids, which are not only used to re-synthesize hepatic 
GSH but are also metabolized to serve as energy substrates in the Krebs 
cycle. This difference in protection between GSH and NAC can be eliminated 
if higher doses of NAC are used. 
Mechanisms of protection I: preventing covalent binding.  
The best established and most effective mechanism of protection by GSH or 
NAC is to enhance the scavenging capacity for NAPQI in hepatocytes. This 
prevents covalent modification of cellular proteins and thereby blocks the 
initiation of APAP toxicity (Corcoran et al., 1985; Lauterburg et al., 1983). 
Intravenously administered GSH is rapidly degraded in the kidney with a 
half-life in plasma of <2 min and the individual amino acids are re-absorbed 
(Wendel and Jaeschke, 1982). NAC or the amino acids of GSH are taken up 
into hepatocytes and are being used for re-synthesis of hepatocellular GSH, 
which is consumed by conjugation with NAPQI (Corcoran et al., 1985; 
Corcoran and Wong, 1986; Lauterburg et al., 1983). Despite the capacity of 
NAC to directly react with NAPQI, it has been clearly demonstrated that the 
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protection of NAC or GSH against APAP overdose requires the synthesis of 
GSH (Corcoran et al., 1985; Corcoran and Wong, 1986; Lauterburg et al., 
1983; Wendel and Jaeschke, 1982). However, in order to be effective through 
this mechanism, GSH or NAC has to be administered during the metabolism 
phase of APAP toxicity. The delayed presentation of overdose patients to the 
emergency room can limit the efficacy of NAC through this mechanism. 
Mechanisms of protection II: scavenging of reactive oxygen species and 
peroxynitrite. Covalent binding of NAPQI to mitochondrial proteins is a 
critical step that links the metabolic activation of APAP to the mitochondrial 
dysfunction (Nelson, 1990). This leads to inhibition of mitochondrial 
respiration with enhanced formation of reactive oxygen species and 
peroxynitrite in mitochondria (Cover et al., 2005b; Jaeschke, 1990; Knight et 
al., 2001; Tirmenstein and Nelson, 1990). The oxidant stress can directly 
trigger the mitochondrial membrane permeability transition pore opening with 
collapse of the mitochondrial membrane potential (Kon et al., 2004). In 
addition, the oxidant stress can activate the cjun N-terminal kinase, which can 
translocate to the mitochondria and facilitate the mitochondrial membrane 
permeability transition pore opening (Hanawa et al., 2008). Either mechanism 
assumes a critical role of mitochondrial reactive oxygen species and 
peroxynitrite formation in the pathophysiology. The toxicity of these reactive 
oxygen and reactive nitrogen species is potentiated by the fact that 
mitochondrial GSH levels are severely depleted during APAP metabolism, 
 88
which leaves these cell organelles highly vulnerable (Knight et al., 2001). 
Thus, delayed treatment with GSH or NAC can accelerate the recovery of 
mitochondrial GSH levels and scavenge reactive oxygen and reactive 
nitrogen species (James et al., 2003c; Knight et al., 2002). Despite the initial 
covalent binding, this treatment limits cellular necrosis, improves survival and 
facilitates repair of the damaged tissue (Bajt et al., 2003). Thus, a critical 
second mechanism of protection by NAC and GSH is the protection against 
oxidant stress and peroxynitrite specifically in mitochondria. 
Mechanisms of protection III: mitochondrial energy substrates. The 
higher efficacy of GSH versus an equimolar dose of NAC in protecting against 
APAP suggests the involvement of a third mechanism. As was shown, both 
GSH and NAC provide enough cysteine to allow for an effective re-synthesis 
of the depleted cellular GSH levels. However, two critical differences between 
GSH- and NAC-treated animals emerged. First, cellular ATP levels were 
significantly better preserved with GSH treatment than with NAC. Based on 
the higher substrate supply for the Krebs cycle, this was most likely caused by 
the use of the excess amino acids not needed for GSH synthesis as energy 
substrates. The higher ATP levels support energy-requiring cellular functions 
including the maintenance of ion gradients by Na+/K+-ATPase and 
Ca2+-ATPase. Dysfunction of these enzymes has been implicated in necrotic 
cell death (Carini et al., 1995; Tsokos-Kuhn et al., 1988). Although the Km of 
ATP for transporters and enzymes is lower than the declining tissue ATP 
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levels after APAP treatment, it needs to be kept in mind that these 
concentrations represent the average in tissue homogenates, which includes 
healthy as well as dying cells. Thus, one would expect that ATP levels in cells 
of the centrilobular area are much lower than the average, and may well be in 
the range of the Km for ATP-dependent transporters and enzymes. In addition, 
the improved energy supply to mitochondria may be responsible for the 
accelerated uptake of cytosolic GSH into mitochondria, as was observed after 
GSH treatment. GSH is transported into mitochondria by the dicarboxylate 
carrier and the oxoglutarate carrier, which mediate electroneutral exchange of 
dicarboxylates for inorganic phosphate and 2-oxoglutarate for other 
dicarboxylates, respectively (Fernandez-Checa and Kaplowitz, 2005; Lash, 
2006; Zhong et al., 2008). During the post-metabolism phase of APAP toxicity, 
mitochondrial GSH is most critical for the effective scavenging of reactive 
oxygen species and specifically peroxynitrite (Knight et al., 2002). The higher 
mitochondrial GSH levels and the reduced areas of nitrotyrosine staining 
correlated with the reduced areas of necrosis after GSH compared to NAC 
treatment. Supply of cysteine without providing additional energy substrates 
leads to sub-optimal protection as was observed with NAC treatment. 
However, supply of excess amino acids without cysteine leads to a partial 
recovery of ATP levels without GSH synthesis, but fails to prevent liver cell 
necrosis. This indicates that just supporting mitochondrial energy metabolism 
alone is insufficient to prevent cell death. These data extend previous data 
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obtained on the effects of NAC and GSH in non-acetaminophen toxicity in 
mice. In particular, NAC significantly increased the flux through PDH, an effect 
which has been shown to be uncoupled from GSH synthesis, and was 
associated with the prevention of liver injury induced by 
tert-butylhydroperoxide and 3-nitropropionic acid. This study also showed that 
NAC has a limited capacity to increase GSH de novo synthesis, but that the 
administration of the GSH precursor cysteine alone in equimolar 
concentrations to NAC does not protect from a disturbed mitochondrial 
energy metabolism (Zwingmann and Bilodeau, 2006). The present study 
provides evidence that injection of GSH itself or of excess amino acids in 
APAP-treated animals clearly results in a better recovery of ATP levels. It 
further suggests a dual role of GSH supplementation in prevention of 
mitochondrial energy failure together with cellular GSH supply. This would 
also explain the higher efficiency when increasing the NAC doses and 
therefore of the amino acid cysteine. Thus, based on these observations it 
can be concluded that a combination of cysteine supply for glutathione 
synthesis and excess amino acids for metabolism in the Krebs cycle provides 
the most effective protection against APAP-induced mitochondrial dysfunction 
and necrotic cell death during the later, postmetabolism phase of the injury. 
This effect can be achieved by injection of either GSH or NAC in sufficient 
quantities. Although the present data show that at a dose of 0.65 mmol/kg 
GSH is more effective than NAC, the effect is clearly caused by the 3-fold 
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higher amount of amino acids injected with GSH compared to an equimolar 
dose of NAC. In fact, a 3-fold higher dose of NAC shows equally effective 
protection as with GSH or the mixture of the individual amino acids of GSH. 
Because the practice guidelines for the use of NAC recommend much higher 
doses than would be needed for the re-synthesis of hepatic GSH levels alone 
(Polson and Lee, 2005), our data suggest that the reason for the efficacy of 
high doses of NAC at these later time points is caused by recovery of hepatic 
and in particular mitochondrial GSH levels, and the improved mitochondrial 
bioenergetics.  
In summary, our data indicate that the amino acids supplied with the 
delayed treatment of GSH or NAC are being used for the re-synthesis of 
hepatic glutathione levels, which protect against cell injury by scavenging 
reactive oxygen species and peroxynitrite in mitochondria. However, excess 
amino acids, i.e. amino acids not used for GSH synthesis, serve as energy 
substrates for the Krebs cycle and support the improved maintenance of 
hepatic ATP levels. Thus, the optimal protection by delayed GSH or NAC 
treatment involves the combination of two mechanisms, i.e., the accelerated 
recovery of mitochondrial GSH levels and support of the mitochondrial 
bioenergetics. These new findings provide the rationale for the clinical use of 
high doses of NAC well beyond the metabolism of APAP. In addition, these 
data suggest that more effective substrates for the mitochondrial energy 
metabolism than excess NAC may further limit cell death and improve 
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regeneration after APAP overdose. 
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CHAPTER 5: MECHANISM OF PROTECTION BY METALLOTHIONEIN 
AGAINST ACETAMINOPHEN HEPATOTOXICITY 
5.1 Abstract. 
Acetaminophen (APAP) overdose is the most frequent cause of 
drug-induced liver failure in the US. Metallothionein (MT) expression 
attenuates APAP-induced liver injury. However, the mechanism of this 
protection remains incompletely understood. To address this issue, C57BL/6 
mice were treated with 100 µmol/kg ZnCl2 for 3 days to induce MT. 
Twenty-four hours after the last dose of zinc, the animals received 300 mg/kg 
APAP. Liver injury (plasma ALT activities, area of necrosis), DNA 
fragmentation, peroxynitrite formation (nitrotyrosine staining), MT expression, 
hepatic glutathione (GSH) and glutathione disulfide (GSSG) levels were 
determined 6 h after APAP alone caused severe liver injury with oxidant 
stress (increased GSSG levels), peroxynitrite formation and DNA 
fragmentation, all of which were attenuated by zinc-induced MT expression. 
In contrast, MT knockout mice were not protected by zinc. Hydrogen 
peroxide-induced cell injury in primary hepatocytes was dependent only on 
the intracellular GSH levels but not on MT expression. Thus, the protective 
effect of MT in vivo was not due to the direct scavenging of reactive oxygen 
species and peroxynitrite. Zinc treatment had no effect on the early GSH 
depletion kinetics after APAP administration, which is an indicator of the 
metabolic activation of APAP to its reactive metabolite 
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N-acetyl-p-benzoquinoneimine (NAPQI). However, MT was able to effectively 
trap NAPQI by covalent binding. We conclude that MT scavenges some of the 
excess NAPQI after GSH depletion and prevents covalent binding to cellular 
proteins, which is the trigger for the propagation of the cell injury mechanisms 
through mitochondrial dysfunction and nuclear DNA damage.  
 
5.2 Introduction. 
 Acetaminophen (APAP) is a widely used analgesic and antipyretic 
drug. Although safe at therapeutic levels, an overdose can cause severe liver 
injury in animals and in humans (Larson et al., 2005). The toxicity is 
dependent on the metabolic activation of APAP via cytochrome P-450, which 
results in the formation of an electrophilic reactive metabolite, 
N-acetyl-p-benzoquinone imine (NAPQI) (Nelson, 1990). NAPQI is rapidly 
conjugated with glutathione (GSH) and the GSH-APAP adduct is excreted 
mainly into bile (Nelson, 1990). However, after the cellular GSH content is 
exhausted, NAPQI covalently binds to cellular proteins (Cohen and Khairallah, 
1997; Jollow et al., 1973) including mitochondrial proteins (Qiu et al., 2001; 
Tirmenstein and Nelson, 1989). This covalent binding is thought to be 
responsible for the mitochondrial dysfunction observed after APAP overdose, 
including inhibition of mitochondrial respiration, ATP depletion, release of 
intermembrane proteins, and mitochondrial oxidant stress and peroxynitrite 
formation (Jaeschke and Bajt, 2006). The characteristic nuclear DNA damage 
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after APAP overdose (Ray et al., 1990) is initially linked to mitochondrial Bax 
translocation (Bajt et al., 2008) and later to oxidant stress/peroxynitrite 
formation and mitochondrial dysfunction (Cover et al., 2005b). The opening of 
mitochondrial membrane permeability transition (MPT) pores with collapse of 
the membrane potential and declining ATP levels (Kon et al., 2004) together 
with the extensive nuclear DNA damage (Shen et al., 1991) are the main 
reasons for the massive oncotic necrotic cell death after APAP overdose 
(Gujral et al., 2002). In addition to the intracellular signaling pathways of 
APAP-induced liver injury, a potential contribution of inflammatory cells is 
extensively but controversially discussed (Jaeschke, 2005, 2008; Liu et al., 
2006). For example, investigations into the role of neutrophils yielded 
opposite results using the same neutropenia-inducing antibody (Cover et al., 
2006; Liu et al., 2006). We suggested that the different results were caused 
by the prolonged pretreatment regimen in one of the studies that lead to a 
preconditioning effect with induction of several acute phase genes, in 
particular metallothionein (MT) (Jaeschke and Liu, 2007). Upregulation of any 
of these genes rather than neutropenia could have been the reason for the 
protection of the anti-neutrophil antibody. However, in order to address this 
complex problem, it is necessary to understand the mechanism by which 
some of these individual genes including MT could protect against 
APAP-induced hepatotoxicity.  
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MT, a ubiquitous heavy metal binding and cysteine-rich protein (Klaassen et 
al., 1999), has been suggested to react with free radicals and organic 
electrophiles (Cagen and Klaassen, 1980). Studies of APAP hepatotoxicity 
demonstrated enhanced liver injury and mortality in metallothionein-deficient 
mice (Liu et al., 1999; Rofe et al., 1998). In addition, induction of MT 
attenuated APAP-induced liver injury (Chengelis et al., 1986; Szymanska et 
al., 1991). The modulation of toxicity was independent of the P450 levels and 
the metabolic activation of APAP (Liu et al., 1999; Rofe et al., 1998). In 
contrast, the protection appeared to be correlated with an antioxidant function 
of MT (Liu et al., 1999). However, no direct evidence for this mechanism 
exists in vivo. In particular, it remains unclear whether MT can actually 
scavenge reactive oxygen species (ROS) and peroxynitrite, which are critical 
mediators of MPT and cell death (Jaeschke et al., 2003). Thus, the main 
objective of this investigation was to investigate the mechanism by which 




Hepatic MT induction by ZnCl2.  
Treatment with a non-toxic dose of ZnCl2 for 3 days resulted in a 100-fold 
increase of MT-1 mRNA expression and a 190-fold increase in MT-2 (Figure 
5.1 A). No other gene quantified showed a significant change including 
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CuZnSOD, MnSOD, GPx1, catalase, HO-1, HSP70, TNF-α, IL-1β, IL-10, KC, 
MIP-2, iNOS or ICAM-1 (data not shown). Similar gene expression profiles 
were recently reported for the same dose of ZnCl2 given over 4 days (Liu et al., 
2009). The increase in MT mRNA translated into extensive MT protein 
expression, as indicated by western blot analysis (Figure 5.1 B) and 
immunohistochemical staining of liver sections (Figure 5.1 C).  
Hepatic MT induction protects against APAP toxicity.  
A dose of 300 mg/kg of APAP-induced severe liver injury at 6 h as indicated 
by the increase in plasma ALT activities and extensive liver necrosis (Figure 
5.2, 5.3). Pretreatment with ZnCl2 attenuated the increase in plasma ALT 
levels by 68% and reduced the area of necrosis by 62% compared to APAP 
alone (Figure 5.2, 5.3). A similar protective effect was observed at 24 h (data 
not shown). To investigate the mechanism of protection, liver sections were 
stained for nitrotyrosine protein adducts, which is an indicator of peroxynitrite 
formation, and the TUNEL assay, an indicator for nuclear DNA fragmentation. 
Whereas there was no nitrotyrosine or TUNEL staining in untreated controls 
(data not shown), extensive centrilobular areas stained positive for both 
nitrotyrosine and DNA fragmentation 6 h after APAP treatment (Figure 5.3). 
The staining correlated with the area of necrosis as assessed in H&E stained 
sections (Figure 5.3). Pretreatment with ZnCl2 substantially reduced both 
nitrotyrosine staining and the number of TUNEL-positive cells (Figure 5. 3). 
Because most peroxynitrite is being formed in mitochondria (Cover et al., 
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2005b), these data suggest that MT induction either prevented the 
mitochondrial oxidant stress or scavenged peroxynitrite.  
MT induction prevents against APAP-induced oxidant stress.  
In a previous study, we demonstrated that ROS (mainly hydrogen peroxide) 
but not peroxynitrite was responsible for GSSG formation in the liver after 
APAP overdose (Knight et al., 2002). To assess whether MT can scavenge 
hydrogen peroxide in vivo, hepatic GSH and GSSG levels were measured in 
the liver (Figure 5.4). At 6 h after APAP treatment, total glutathione 
(GSH+GSSG) levels only partially recovered (Figure 5.4 A), the GSSG 
content was significantly increased (Figure 5.4 B) and the GSSG-to-GSH ratio 
was increased from 0.5% to 2.5% (Figure 5.4 C). The data indicate a 
significant oxidant stress in these livers consistent with previous reports that 
identified this GSSG increase as being predominantly in mitochondria 
(Jaeschke, 1990; Knight et al., 2001). Induction of MT with ZnCl2 improved 
the recovery of hepatic GSH levels, attenuated the increase in GSSG content 
and significantly reduced the GSSG-to-GSH ratio (Figure 5.4 A-C). These 
results suggest that MT induction attenuated the formation of reactive oxygen 
species in vivo rather than scavenged them. To directly assess whether MT is 
able to scavenge reactive oxygen species in intact cells, isolated mouse 
hepatocytes were exposed to various concentrations of hydrogen peroxide 
(H2O2), the ROS most likely responsible for the elevated GSSG levels. H2O2 
dose-dependently caused cell injury as indicated by LDH release (Figure 5.5 
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A,B). However, pretreatment with ZnCl2 did not affect the injury in normal cells. 
In contrast, prior depletion of GSH substantially aggravated H2O2 – induced 
cell death (Figure 5.5 A,B). In agreement with these results, ZnCl2 – 
pretreatment did not affect cell injury in GSH-depleted hepatocytes (data not 
shown). Together these data suggest that intracellular GSH was able to 
detoxify H2O2 diffusing into the cell. However, intracellular MT expression did 
not impact ROS-mediated toxicity indicating that MT, in contrast to GSH, did 
not detoxify H2O2. Overall, the combined in vitro and in vivo data suggest that 
MT prevented APAP-induced ROS formation rather than scavenged ROS.             
MT induction did not affect NAPQI formation.  
The fact that MT induction prevented the oxidant stress indicates that MT 
must have acted upstream of mitochondria. To evaluate whether ZnCl2 
treatment affected NAPQI formation, the initial depletion kinetics of GSH was 
measured. During the first 20 min after APAP injection, the rapid decline of 
hepatic GSH levels is caused almost exclusively by NAPQI formation 
(Jaeschke, 1990). Controls and ZnCl2 – treated animals showed a similar rate 
of GSH loss during the first 20 min (Figure 5.6). However, livers from ZnCl2 – 
treated mice had significantly higher basal GSH levels than livers from control 
animals (Figure 5.6). The difference was maintained during the first 20 min 
and disappeared when GSH depletion in controls slowed down more rapidly 
compared to the ZnCl2 - treated animals (Figure 5.6). Together, these data 
suggest that NAPQI formation was not impaired by MT induction, but the 
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livers from ZnCl2 - treated animals had a higher capacity to detoxify NAPQI. 
The slightly higher GSH level may have been a contributing factor but was 
unlikely the only reason for the effective protection against APAP-induced 
liver injury. 
MT can scavenge and covalently bind NAPQI.  
Because MT induction did not reduce NAPQI formation but prevented the 
mitochondrial oxidant stress, which is assumed to be caused by NAPQI 
binding to mitochondrial proteins, the only remaining intervention point could 
be the direct scavenging of NAPQI by MT. To test this hypothesis, a solution 
of purified MT (1 mg/ml) was mixed with NAPQI solution (12 µg/ml) at 4oC and 
transferred immediately or after 2 h of incubation at 4oC to the loop of an 
HPLC connected online to a mass spectrometer and analyzed as indicated in 
material and methods (Figure 5.7). As a control sample, an aliquot of MT kept 
under the same conditions, but without the addition of NAPQI, was analyzed 
under the identical conditions. This control sample showed multiple ions in the 
m/z range 1537-1566, corresponding to the +4 charge state of the protein 
(Figure 5.7 A). This is consistent with the presence of several isoforms of MT 
in the commercially available form of the protein. Mixing of MT with NAPQI 
resulted in the immediate disappearance of the ions at m/z range 1537-1566 
with a time-dependent formation of a series of ions at a higher m/z range 
(1592-1644) (Figure 5.7 B). Four of these ions, at m/z at 1637.6, 1643.7, 
1666.4 and 1671.7, are clearly newly formed. Other ions, at m/z at 1592.7, 
 101 
1611.6 and 1618.3, appear on top of small ions present in the commercial 
preparation of MT. However, their relative change in intensity indicates that 
these ions are also the result of the reaction of NAPQI with MT. The dead time 
between the addition of NAQPI and the injection on the loop of the HPLC to 
start the chromatographic separation was 20 sec. This reaction is complete 
following 2 h incubation at 4oC (Figure 5.7 C). Because of the complexity of 
the resulting mass spectra, the exact pair of shifts in mass can not be 
determined with absolute certainty. However, given the accuracy of the mass 
measurement and the fact that the reaction of NAPQI with proteins results in 
an increase in mass of 149.1 Dalton (Hoos et al., 2007), it is possible to 
assume that most of the isoforms of MT reacted with one, two or three 
molecules of NAPQI, resulting in a shift of 149 Dalton (from m/z 1554.6 to m/z 
1592.8), 298 Dalton (from m/z 1537.1, 1545.2, 1561.2 to 1565.6 to 1611.6, 
1683.3, 1637.6 and 1643.7, respectively ) or 447 Dalton (from m/z 1554.7 and 
1561.2 to 1565.4 and 1671.6, respectively). 
MT induction is responsible for ZnCl2-induced protection against 
APAP-induced hepatotoxicity.  
To verify that MT gene expression was indeed the mechanism by which Zn 
reduced APAP-induced liver injury, 129S1/SvImJ wildtype and MT-deficient 
mice were treated with APAP for 6 h. Based on plasma ALT activities and the 
area of necrosis, APAP caused severe liver injury, which was significantly 
attenuated in Zn-treated wildtype animals but not in MT-deficient mice (Figure 
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5.8). These data support the conclusion that MT gene expression is the main 












Quantitative real-time PCR was used to analyze for MT-1 and MT-2 mRNA 
expression in livers of animals treated with saline (6 ml/kg) (controls, C) or 
100 µmol/kg ZnCl2 for 3 days. MT mRNA is expressed as the MT-to-actin ratio 
(A). Data represent mean + SE of n = 4 animals *P<0.05 (compared to C). 
Western blot analysis of MT protein in controls and ZnCl2-treated animals (B). 
Immunohistochemical analysis of MT expression in control liver compared to 









Liver injury was evaluated by measuring plasma alanine aminotransferase 
(ALT) activities (panel A) and quantitating the area of necrosis (panel B) in 
untreated animals (C) and 6 h after injection of 300 mg/kg acetaminophen 
(APAP). Animals were either treated with saline (6 ml/kg) or 100 µmol/kg 
ZnCl2 for 3 days. APAP was injected 24 h after the last dose of Zn/saline. 
Data represent means ± SE of n = 5 animals per group. *P<0.05 (compared to 








Representative liver sections of animals treated for 6 h with 300 mg/kg 
acetaminophen were stained with H&E (assess area of necrosis), a 
nitrotyrosine antibody (marker of peroxynitrite formation) and the TUNEL 
assay (marker for DNA strandbreaks). Animals were either treated with saline 
(6 ml/kg) or 100 µmol/kg ZnCl2 for 3 days. APAP was injected 24 h after the 







Total glutathione (GSH+GSSG) (panel A) and glutathione disulfide (GSSG) 
(panel B) levels were measured and the GSSG-to-GSH ratio (panel C) was 
calculated 6 h after treatment with 300 mg/kg APAP. Animals were either 
treated with saline (6 ml/kg) or 100 µmol/kg ZnCl2 for 3 days. APAP was 
injected 24 h after the last dose of Zn/saline. Data represent means ± SE of n 







Primary cultured murine hepatocytes were exposed to various concentrations 
of hydrogen peroxide (H2O2) or vehicle (culture medium) for up to 4 h and cell 
injury was measured as % of released lactate dehydrogenase (LDH). Animals 
used for cell isolation were either untreated or received 100 µmol/kg ZnCl2 for 
3 days or 100 mg/kg phorone 90 min before isolation. All cells isolated from 
phorone-treated animals were cultured in the presence of 1 mM buthionine 
sulfoximine to inhibit GSH synthesis. All data represent means ± SE of 4 








Hepatic glutathione levels (GSH+GSSG) were measured at early time points 
(0 – 40 min) after administration of 300 mg/kg acetaminophen. Animals were 
either treated with saline (6 ml/kg) or 100 µmol/kg ZnCl2 for 3 days. APAP was 
injected 24 h after the last dose of Zn/saline. Data represent means ± SE of n 









Rabbit liver MT was analyzed by reverse phase chromatography/mass 
spectrometry as described in the experimental procedures. The figure shows 
the +4 charge state protein ions obtained on the IT of the control sample. An 
aliquot of MT that was not reacted with NAPQI (A), or following the addition of 
NAPQI and incubation at 4 °C for 20 sec (B) or 2h (C). For each panel, data 
are reported as percentage relative to the most intense ion. Thus, the 
progress of the reaction is indicated by a change in the relative intensities of 
the ions present at each experimental time. There is a decrease of the 
intensity of the ions in the m/z range 1537-1565 with a concomitant increase 












Liver injury was evaluated by measuring plasma alanine aminotransferase 
(ALT) activities (panel A) and quantitating the area of necrosis (panel B) in 
wildtype and MT-1/MT-2-deficient (MT KO) mice 6 h after injection of 300 
mg/kg acetaminophen (APAP). Animals were either treated with saline (6 
ml/kg) (S) or 100 µmol/kg ZnCl2 for 3 days. APAP was injected 24 h after the 
last dose of Zn/saline. Data represent means ± SE of n = 4-6 animals per 















See text for details. Abbreviations: AIF, apoptosis-inducing factor; EndoG, 
endonuclease G; GSSG, glutathione disulfide; MPT, mitochondrial membrane 
permeability transition pore; MT, metallothionein; NAPQI, 
N-acetyl-p-benzoquinone imine; NT adducts, nitrotyrosine protein adducts; 




The objective of this investigation was to evaluate the mechanism(s) 
of protection of MT induction by ZnCl2 against APAP hepatotoxicity. Our data 
support the conclusion that ZnCl2 selectively induced MT gene expression, 
which did not scavenge reactive oxygen species but appeared to prevent the 
oxidant stress by scavenging the reactive metabolite NAPQI. 
It is well established that heavy metals including Zn can induce MT gene 
expression in the liver (Klaassen et al., 1999; Liu et al., 2009). The present 
data confirmed this observation and showed that both MT-1 and MT-2 mRNA 
levels were induced in the liver and that this translated into a substantial 
increase in MT protein expression in hepatocytes. Despite the effective 
induction of MT by Zn, there is some controversy whether this is the main 
mechanism by which Zn can protect against drug-induced liver injury. For 
example, Zn supplementation in the diet attenuated alcoholic liver injury in 
MT-deficient mice during a 12-week study suggesting that the protection was 
independent of MT (Zhou et al., 2005). However, the average oral Zn intake 
was calculated to be 33 mg/kg/day (505 µmol/kg/day), which is about 5 times 
higher than the subcutaneous dose used in the present investigation for 3 
days. A similar s.c. treatment of Zn did not protect MT-deficient mice against 
APAP-induced liver injury (Liu et al., 2009). We could confirm these findings 
(Figure 5.8) suggesting that MT induction was the principle mechanism of 
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protection. In addition, we showed that 100 µmol/kg/day ZnCl2 selectively 
induced MT but did not affect a number of other genes, whose upregulation 
has been shown to be beneficial against APAP-induced liver injury. This 
includes HO-1 (Chiu et al., 2002), HSP70 (Tolson et al., 2006) and MnSOD 
(Fujimoto et al., 2009). A recent genomic study using the same dose of Zn 
reported similar findings (Liu et al., 2009). These data together suggest that 
the protective effect of ZnCl2 treatment was mainly caused by MT induction in 
hepatocytes. However, the slightly higher hepatic GSH levels in ZnCl2-treated 
animals may have also contributed to the protection. This effect of Zn could 
have been caused by the moderate upregulation of nuclear factor-erythroid 
2-related factor 2 (Nrf2) (Liu et al., 2009), which positively regulates GSH 
synthesizing enzymes (Lu, 2009).      
 
It has been extensively postulated that MT can scavenge reactive oxygen 
species (Kumari et al., 1998; Sato and Bremner, 1993; Thornalley and Vasak, 
1985). However, most studies were done with isolated proteins in a test tube. 
In an in vivo study where it was concluded that MT protected against APAP 
toxicity by acting as ROS scavenger it remained unclear whether MT 
prevented formation of ROS or scavenged them (Liu et al., 1999). Our in vivo 
data demonstrated that MT induction reduced nitrotyrosine staining and 
prevented DNA fragmentation, which is dependent on mitochondrial 
peroxynitrite formation and dysfunction (Bajt et al., 2008; Cover et al., 2005b). 
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These results can be interpreted as if MT acted as an effective scavenger of 
peroxynitrite in the mitochondria or that MT acted upstream and prevented the 
formation of ROS. The fact that MT induction reduced hepatic GSSG levels 
and the GSSG-to-GSH ratio after APAP, suggestes that the formation of ROS, 
especially hydrogen peroxide, was prevented. This conclusion is supported 
by previous findings showing that GSSG levels remained elevated when only 
peroxynitrite is scavenged, but ROS formation is unaffected (Knight et al., 
2002). In addition, the experiments with isolated hepatocytes exposed to 
various concentrations of hydrogen peroxide did not indicate that MT was 
able to effectively scavenge ROS in the presence or absence of GSH. In 
contrast, GSH was the critical antioxidant controlling ROS-induced cell death 
in hepatocytes. This shows that hydrogen peroxide entered the cells and a 
competent scavenger (GSH) was able to intercept this oxidant in the cytosol. 
In general, peroxides diffuse into the cell, trigger mitochondrial dysfunction 
and ultimately cause MPT pore formation and cell necrosis (Nieminen et al., 
1995). Although most MT is expressed in the cytosol after induction, MT did 
not affect cell injury. This indicates that MT is not a relevant scavenger of 
hydrogen peroxide, which suggests that the reduced hepatic GSSG levels 
and the reduced GSSG-to-GSH ratio in APAP-treated animals are unlikely to 
be caused by the scavenging of ROS, especially not in the presence of GSH. 
Thus, our findings indicate that MT acted upstream of the initiation of the 
mitochondrial oxidant stress. 
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The main event upstream of mitochondrial protein binding is the formation of 
the reactive metabolite NAPQI. Inhibition of the metabolic activation is most 
effective in preventing APAP toxicity. Because NAPQI is detoxified by GSH, 
the initial decline of the hepatic GSH levels reflects the formation of NAPQI 
(Jaeschke, 1990). Based on the GSH depletion kinetics, there was no 
relevant difference between controls and ZnCl2-treated animals, suggesting 
that there was no difference in NAPQI formation. However, it was observed 
that the basal GSH levels after ZnCl2 were higher than in controls. Although 
the difference was only 11%, the data indicate a slightly higher capacity to 
detoxify NAPQI in the ZnCl2-treated livers. This effect may have contributed to 
the protective effect of ZnCl2 treatment against APAP toxicity. Nevertheless, it 
is unlikely that this limited amount of additional GSH could have been entirely 
responsible for the protection against APAP toxicity.  
 
The only remaining explanation for the protective effect of MT after NAPQI 
formation, but before mitochondrial protein binding, would be a direct 
scavenging of NAPQI by MT. Due to its high content of cysteine residues, MT 
can react with organic electrophiles (Cagen and Klaassen, 1980) including 
NAPQI (Roberts et al., 1987). Our mass spectrometric data confirm these 
findings and demonstrate directly a time-dependent covalent binding of 1-3 
NAPQI molecules to each MT protein. Because the depletion kinetics of GSH 
is not affected, these data suggest that MT reacts with NAPQI only when GSH 
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levels are very low. A higher affinity of NAPQI to GSH as compared to the 
sulfhydryl groups of MT has also been observed with other electrophiles 
(Cagen and Klaassen, 1980). These findings indicate that MT induction is not 
a primary detoxification mechanism for organic electrophiles, but MT can 
become important once GSH is depleted as it is after APAP overdose.         
 
In summary, we demonstrated that ZnCl2 treatment effectively attenuated the 
APAP-induced mitochondrial oxidant stress and peroxynitrite formation, 
nuclear DNA damage and necrotic cell death (Figure 9). Because 
MT-deficient mice were not affected by Zn treatment, the protective effect was 
mainly caused by the induction of MT protein expression in hepatocytes. The 
slightly higher GSH levels observed in ZnCl2-treated animals may have also 
contributed to the protection. The induction of MT did not affect the metabolic 
activation of APAP but attenuated the oxidant stress. However, lower hepatic 
GSSG levels after APAP and no evidence that MT was able to scavenge ROS 
in vitro suggested a target upstream of mitochondria. MT was able to 
effectively react with NAPQI once GSH was depleted. Thus, our data are 
consistent with the conclusion that MT acts as a second line of defense 
behind GSH to scavenge NAPQI and prevent the binding to cellular proteins 
including mitochondrial proteins. This will attenuate the mitochondrial oxidant 
stress and peroxynitrite formation, which are critical mediators of 
APAP-induced liver injury. Because MT can be induced by various cellular 
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stresses it could be target for drug toxicity prophylaxis. As such, MT 
expression could also be an unrecognized mechanism of protection of certain 










CHAPTER 6: ROLE OF C-JUN-N-TERMINAL KINASE IN 
ACETAMINOPHEN-INDUCED LIVER INJURY 
 
6.1 Abstract 
Acetaminophen (APAP) overdose, which causes liver injury in animals and 
humans, activates c-jun N-terminal kinase (JNK). Although it was shown that 
the JNK inhibitor SP600125 effectively reduced APAP-induced hepatotoxicity, 
the mechanisms of protection remain unclear. C57Bl/6 mice were treated with 
10 mg/kg SP600125 or vehicle (8% dimethylsulfoxide) 1h before 600 mg/kg 
APAP administration. APAP time-dependently induced JNK activation 
(detected by JNK phosphorylation). SP600125, but not the vehicle, reduced 
JNK activation, attenuated mitochondrial Bax translocation and prevented the 
mitochondrial release of apoptosis-inducing factor at 4–12 h. Nuclear DNA 
fragmentation, nitrotyrosine staining, tissue GSSG levels and liver injury 
(plasma ALT release and necrosis) were partially attenuated by the vehicle 
(-65%) and completely eliminated by SP600125 (-98%) at 6 and 12h. 
Furthermore, SP600125 attenuated the increase of inducible nitric oxide 
synthase (iNOS) mRNA and protein. However, APAP did not enhance plasma 
nitrite+nitrate levels (NO formation); SP600125 had no effect on this 
parameter. The iNOS inhibitor L-Nil did not reduce NO formation or injury after 
APAP but prevented NO formation caused by endotoxin. Since SP600125 
completely eliminated the increase in hepatic GSSG levels, an indicator of 
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mitochondrial oxidant stress, it is concluded that the inhibition of peroxynitrite 
was mainly caused by reduced superoxide formation. Our data suggest that 
the JNK inhibitor SP600125 protects against APAP-induced liver injury in part 
by attenuation of mitochondrial Bax translocation but mainly by preventing 
mitochondrial oxidant stress and peroxynitrite formation and thereby 
preventing the mitochondrial permeability transition pore opening, a key event 
in APAP-induced cell necrosis.            
 
6.2 Introduction 
An overdose of acetaminophen (APAP), a commonly used analgesic 
drug, can cause hepatic necrosis and even liver failure in humans and 
animals. APAP overdose is currently the most frequent cause of drug-induced 
liver failure in the US (Larson et al., 2005). APAP-induced liver cell injury is 
initiated by the formation of a reactive metabolite, N-acetyl-p-benzoquinone 
imine (NAPQI), which can be generated by several cytochrome P-450 
isoenzymes, especially cyp2E1 (Nelson, 1990). NAPQI is detoxified by 
glutathione (GSH), resulting in the depletion of this sulfhydryl reagent 
(Mitchell et al., 1973). Once cellular GSH is consumed, NAPQI covalently 
binds to cellular proteins (Cohen et al., 1997). However, cell injury correlates 
less with total protein binding but more with the capacity to bind to 
mitochondrial proteins (Tirmenstein and Nelson, 1989). These findings 
support the hypothesis that covalent binding to mitochondrial proteins may be 
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responsible for mitochondrial dysfunction (Jaeschke and Bajt, 2006; 
Jaeschke et al., 2003). The well established effects of an APAP overdose on 
mitochondria include inhibition of mitochondrial respiration, enhanced 
formation of reactive oxygen species and peroxynitrite, mitochondrial DNA 
damage, release of mitochondrial intermembrane proteins, which translocate 
to the nucleus and cause nuclear DNA degradation, and ultimately opening of 
the mitochondrial membrane permeability transition pore with collapse of the 
membrane potential (Jaeschke and Bajt, 2006; Jaeschke et al., 2003).   
 
C-jun-N-terminal kinase (JNK) is a member of the mitogen-activated 
protein kinase (MAPK) superfamily (Hibi et al., 1993). JNK can activate a 
variety of signal cascades through its phosphorylation of not only transcription 
factors such as c-jun (Li et al., 2004b), p53 (Cheng et al., 2003), and ATF-2 
(Hayakawa et al., 2003), but also members of the Bcl-2 family 
(Latchoumycandane et al., 2007). JNK has 2 ubiquitously expressed isoforms 
(JNK1, JNK2) and a tissue-specific isoform (JNK3), which is predominately 
located in neurons of the central nervous system (Resnick and Fennell, 2004). 
JNK1 mediates the majority of c-jun phosphorylation and JNK2 mainly 
regulates c-jun stability (Sabapathy et al., 2004).  
 
Studies with APAP overdose clearly demonstrated prolonged activation 
of JNK before cell death. Furthermore, pharmacological inhibition of JNK or 
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the silencing of JNK gene expression resulted in reduced liver injury after 
APAP overdose (Gunawan et al., 2006; Hanawa et al., 2008; Henderson et al., 
2007). However, the use of JNK-deficient mice yielded mixed results. One 
study showed a partial protection with JNK2- but not JNK1-deficient mice 
(Gunawan et al., 2006). Other studies did not find a protection with either JNK 
knockout mice (Bourdi et al., 2008; Henderson et al., 2007). In contrast, one 
report suggested a beneficial role of JNK2 in tissue repair after APAP (Bourdi 
et al., 2008). Although apoptosis signal-regulating kinase 1 (ASK1), a 
member of the mitogen-activated protein kinase kinase kinase family, has 
been identified as the upstream activator of JNK (Nakagawa et al., 2008a), 
the downstream mechanisms by which JNK affects APAP hepatotoxicity are 
less clear. It was suggested that JNK may act by triggering Bax activation and 
translocation to the mitochondria (Gunawan et al., 2006). However, 
Bax-deficient mice are only temporarily protected against APAP-induced 
hepatotoxicity (Bajt et al., 2008) suggesting that additional mechanisms may 
be operative. More recently it was proposed that JNK is activated by reactive 
oxygen species generated by GSH-depleted mitochondria, which triggers the 
translocation of activated JNK to mitochondria resulting in the induction of the 
mitochondrial permeability transition (Hanawa et al., 2008). A caveat of this 
hypothesis is that reactive oxygen species have not been detected outside 
the mitochondria (Jaeschke, 1990) and that the more aggressive oxidant 
peroxynitrite, generated in mitochondria, was identified as a critical mediator 
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of the injury process (Cover et al., 2005b; Knight et al., 2002). A third 
mechanism, JNK-mediated activation of inducible nitric oxide synthase 
(iNOS), was also suggested (Latchoumycandane et al., 2007). However, 
inhibition of iNOS was not consistently beneficial in APAP hepatotoxicity 
(Gardner et al., 2003; Hinson et al., 2002). Therefore, our goal was to assess 
all three mechanisms simultaneously and evaluate by which mechanism the 
pharmacological and genetic inhibition of JNK protects in an in vivo murine 




Functional significance of JNK activation after APAP overdose: JNK2 
KO Mice 
For studying mechanisms of APAP-induced liver injury, the most frequently 
used dose by us and others is 300 mg/kg in overnight fasted animals (Cover 
et al., 2005a; Gardner et al., 2003; Hinson et al., 1998; Knight et al., 2002; 
Knight et al., 2001). This dose consistently causes severe liver injury in 
almost all mouse strains. Administration of 300 mg/kg APAP resulted in the 
activation of JNK in the livers of C57Bl/6 mice as indicated by the appearance 
of the phosphorylated form (P-JNK) with an early peak at 2 h and second 
peak at 6 h (Figure 1A). At 24 h, no P-JNK was detectable. The 
phosphorylation of both JNK isoforms (JNK1, 46 kDa; JNK2, 54 kDa) 
observed after APAP is consistent with previous reports (Bourdi et al., 2008; 
Hanawa et al., 2008; Henderson et al., 2007; Latchoumycandane et al., 2007; 
Nakagawa et al., 2008b). Delayed treatment with GSH, which effectively 
scavenged peroxynitrite and hydrogen peroxide (Knight et al., 2002) or 
treatment with ZnCl2, which induced metallothionein and partially prevented 
the mitochondrial oxidant stress (Saito et al.) also prevented JNK activation 
(Figure 6.1B). These data suggest that JNK activation is linked to the 
formation of oxidant stress in this model. Both, the scavenging of reactive 
oxygen species by GSH administration and the partial prevention of 
mitochondrial oxidant stress by Zn pretreatment together with the inhibition of 
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JNK activation resulted in significantly reduced liver injury (Figure 6.2A). To 
directly evaluate the pathophysiological role of JNK, wild type and JNK2 KO 
mice were treated with 300 mg/kg APAP. At 6 h, plasma ALT levels increased 
to a similar degree in both WT and JNK2 KO mice (Figure 6.2B) reflecting 
severe centrilobular necrosis (Figure 6.2C). To confirm the findings with JNK2 
KO mice, C57Bl/6 mice were treated with the general JNK inhibitor SP600125 
or the vehicle DMSO/PBS. Although 300 mg/kg APAP alone caused severe 
liver injury at 6 h (plasma ALT: 5220 ± 1085 U/L), treatment with the vehicle 
alone or with SP600125 completely prevented any liver injury (data not 
shown). The reason for the complete protection by the vehicle alone is that 
the dose of DMSO (1.2 ml/kg) necessary to dissolve the inhibitor effectively 
blocks the metabolic activation of APAP (Jaeschke et al., 2006). Thus, a 
higher dose of APAP (600 mg/kg) had to be used to overcome this block 
(Hanawa et al., 2008). 
 
Functional significance of JNK activation after APAP overdose: 
SP600125 
Treatment of C57Bl/6 mice with 600 mg/kg APAP resulted in a rapid loss of 
hepatic GSH content due to NAPQI formation (Figure 6.3). Within 20 min 
GSH levels decreased by 62% and within 2 h 92% was lost. However, 
pretreatment with SP600125 or its vehicle substantially delayed the initial 
decline, but GSH levels had fallen by 81-88% by 2 h (Figure 6.3). These data 
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indicate that the high dose of APAP overcame some of the inhibition of the 
metabolic activation in the presence of DMSO. To evaluate the functional 
significance of JNK, the effect of SP600125 on liver injury was evaluated at 6 
and 12 h after APAP (Figure 6.4 A,B). Compared to PBS-treated animals, the 
DMSO-containing vehicle substantially attenuated liver injury at both 
time-points as reflected by the approximately 65% reduction in ALT release at 
both time points (Figure 6.4A) and the reduced area of necrosis at 12 h 
(Figure 6.4B). However, liver injury was essentially completely prevented by 
pretreatment with SP600125 (Figure 6.4A,B). These findings were confirmed 
by using the TUNEL assay to evaluate nuclear DNA damage (Figure 6.4C). 
Previous reports from our laboratory provided evidence for the translocation 
of mitochondrial intermembrane proteins such as apoptosis-inducing factor 
(AIF) and endonuclease G to the nucleus as the main cause of the nuclear 
DNA damage after APAP overdose (Bajt et al., 2006). This effect was caused 
initially by formation of Bax pores in the outer membrane and subsequently by 
mitochondrial swelling and rupture of the outer membrane due to MPT (Bajt et 
al., 2008). In support of these events, JNK activation, release of AIF into the 
cytosol and translocation of Bax to the mitochondria was observed 12 h after 
APAP (Figure 6.5). Although the vehicle was without effect on these 
parameters, SP600125 effectively reduced JNK activation, mitochondrial AIF 
release and mitochondrial Bax translocation (Figure 6.5). To confirm that 
these events are not just consequences of the protection observed at 12 h, 
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the same parameters were also measured at an earlier time point (4 h) where 
only minimal injury occurred (Figure 6.6). Again, APAP caused JNK activation, 
mitochondrial Bax translocation and release of AIF, all of which were 
effectively attenuated by SP600125 (Figure 6.6). The vehicle DMSO partially 
prevented mitochondrial AIF release but had no relevant effect on JNK 
activation and mitochondrial Bax translocation (Figure 6.6). Together these 
data support the conclusion that JNK activation causes mitochondrial Bax 
translocation, which is responsible for the initial AIF and endonuclease G 
release from the mitochondria and early nuclear DNA damage. However, 
studies with Bax-deficient mice showed no effect of Bax on the mitochondrial 
oxidant stress and peroxynitrite formation, which ultimately were responsible 
for the later release of AIF and endonuclease G and the resulting DNA 
degradation and cell death (Bajt et al., 2008). Since SP600125 effectively 
prevented cell death even at later time points, these data suggest that JNK 
has additional, more critical effects than just causing Bax activation.  
 
Effect of SP600125 on iNOS expression and peroxynitrite formation 
It is well established that APAP overdose causes peroxynitrite formation in 
cells undergoing necrotic cell death (Hinson et al., 1998; Knight et al., 2001). 
To evaluate if JNK activation is associated with peroxynitrite formation, liver 
tissue was stained for nitrotyrosine protein adducts (Figure 6.7). APAP 
overdose caused substantial peroxynitrite formation in centrilobular 
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hepatocytes at 6 h (Figure 6.7) and at 12 h (data not shown). Pretreatment 
with the vehicle DMSO partially reduced, whereas treatment with SP600125 
completely eliminated, nitrotyrosine staining at both 4 and 12 h (Figure 6.7). 
These data suggest that JNK activation is involved in peroxynitrite formation. 
Since it was previously hypothesized that JNK activation may enhance liver 
injury by promoting peroxynitrite formation through iNOS induction 
(Latchoumycandane et al., 2007), the effect of APAP and JNK on iNOS was 
investigated. APAP overdose caused a 3.5-fold and a 7-fold increase of iNOS 
mRNA at 4 and 12h, respectively (Figure 6.8A). This translated into a minor 
increase in iNOS protein expression at 6 h (Figure 6.8B) and at 12 h (data not 
shown). However, plasma nitrite + nitrate levels as indicators of NO formation 
did not change significantly (Figure 6.8C). Although SP600125 attenuated 
iNOS mRNA and protein levels, there was no significant effect on plasma 
nitrite + nitrate concentrations (Figure 6.8). In addition, the iNOS inhibitor L-Nil, 
affected neither plasma nitrite + nitrate levels (Figure 6.8C) nor APAP-induced 
liver injury (Figure 6.8D). As a positive control, LPS treatment substantially 
enhanced plasma nitrite + nitrate concentrations, which where reduced to 
baseline by L-Nil treatment (Figure 6.8C). Although these data confirm that 
JNK was involved in a minor transcriptional induction of iNOS after APAP 
overdose, the beneficial effect of inhibiting JNK activation on peroxynitrite 
formation and liver injury was independent of iNOS. 
Role of JNK in APAP-induced mitochondrial oxidant stress 
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Since APAP-induced peroxynitrite formation did not appear to be caused by 
JNK-mediated enhanced NO generation, especially from iNOS, formation of 
reactive oxygen was assessed. It was previously demonstrated that 
increased tissue levels of GSSG after APAP reflect mainly mitochondrial 
superoxide/hydrogen peroxide but not peroxynitrite formation (Jaeschke, 
1990; Knight and Jaeschke, 2004; Knight et al., 2001). Thus, GSH and GSSG 
levels were measured at 12 h after APAP (Figure 6.9). The total hepatic 
glutathione content (GSH+GSSG) was still partially depleted after treatment 
with APAP alone but GSSG levels were significantly elevated above controls 
(Figure 6.9A,B). This resulted in an increased GSSG-to-GSH ratio from less 
than 0.5 to more than 2.5 (Figure 6.9C). The vehicle-treated group, which was 
partially protected against APAP-induced liver injury (Figure 6.4), showed 
higher total glutathione and GSSG levels resulting in a significantly elevated 
GSSG-to-GSH ratio (Figure 6.9). These data indicate that the vehicle DMSO 
accelerated the recovery of liver GSH levels and improved the detoxification 
of reactive oxygen species but did not prevent the APAP-induced oxidant 
stress. In contrast, the JNK inhibitor SP600125 did not only promote the faster 
recovery of the hepatic GSH content, it completely prevented the increase in 
GSSG levels and the change in the GSSG-to-GSH ratio (Figure 6.9). These 
data are consistent with the conclusion that the JNK inhibitor completely 
prevented the APAP-induced oxidant stress. 
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Late treatment with GSH inhibits JNK activation 
It was previously shown that delayed treatment with GSH up to 2.5 h protects 
against APAP hepatotoxicity by stimulating hepatic GSH synthesis and 
replenishing mitochondrial GSH levels, which scavenge reactive oxygen and 
peroxynitrite, as well as support the mitochondrial energy metabolism (Knight 
et al., 2002; Saito et al., 2009). Treatment with GSH 4 h after APAP enhanced 
hepatic GSH levels (Figure 6.10C) and strongly reduced JNK activation at 6 h 
in the APAP and the APAP/DMSO group (Figure 6.10A). SP600125 treatment 
alone prevented JNK activation and GSH administration did not affect these 
results despite inducing the highest GSH levels (Figure 6.10). Interestingly, 
DMSO did not affect JNK activation but reduced plasma ALT values by 71% 
(Figure 6.10B). In addition, delayed GSH treatment significantly reduced liver 
injury in the APAP group by 62% and in the APAP/DMSO group by 60% 
(Figure 6.10B). Despite a similar degree of low P-JNK expression in 4 groups, 
there were substantial differences in injury between the groups. These data 
suggest that scavenging mitochondrial reactive oxygen and peroxynitrite 
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JNK activation in response to treatment with 300 mg/kg acetaminophen 
(APAP).  A. Time course of P-JNK formation as indicator of JNK activation in 
response to APAP treatment. β-actin protein expression is shown as loading 
control. B. Total JNK and P-JNK protein expression were measured in 
untreated controls (C) and in animals treated with 300 mg/kg APAP alone or 
together with either 0.65 mmol/kg GSH (i.v.) administered at 1.5 h after APAP 
or 100 µmol/kg ZnCl2 administered for 3 days as described in details in the 










































Plasma alanine aminotransferase (ALT) activities as an indicator for 
APAP-induced hepatotoxicity were measured in C57BL/6 mice 6 h after 300 
mg/kg APAP administration. A. Animals were either untreated (C) or received 
APAP alone or together with GSH at 1.5 h after APAP or with 100 µmol/kg 
ZnCl2. Data represent means + SE of n = 4 animals per group. *P<0.05 
(compared to C), #P<0.05 (compared to APAP). B. Plasma ALT activities were 
measured in wild type and JNK2-deficient (JNK2 KO) mice 6 h after injection 
of 300 mg/kg APAP. Data represent means + SE of n = 4 animals per group. 
*P<0.05 (compared to untreated controls). C. Representative liver sections of 
animals treated for 6 h with 300 mg/kg APAP were stained with H&E (assess 








The liver content of total glutathione (GSH + GSSG) was determined in 
untreated controls (C) or 20 min or 2 h after injection of APAP (600 mg/kg, ip). 
Some of the animals were pretreated with either 15ml/kg PBS, 15 ml/kg 
DMSO (8.3% in PBS) or SP600125 (10 mg/kg in DMSO/PBS). Data represent 
means ± SE of n = 4 animals per group. *P<0.05 (compared to C) #P<0.05 






























    
 







A. Plasma ALT activities were measured in untreated controls (C) and at 6 or 
12 h after administration of 600 mg/kg APAP in mice with either 15 ml/kg PBS, 
15 ml/kg DMSO in PBS or 10 mg/kg of the JNK inhibitor SP600125 at 1 h 
before APAP. Data represent means ± SE of n= 4-6 animals per group. 
*P<0.05 (compared to C), #P<0.05 (compared to APAP-PBS) and $P<0.05 
(compared to DMSO). B. Histological assessment of liver injury in 
representative H&E-stained tissue sections obtained 12 h after APAP 
administration. C. DNA fragmentation was evaluated by the TUNEL assay in 





































P-JNK and JNK protein expression were determined in whole liver 
homogenates by Western blot analysis in untreated controls or at 12 h after 
APAP (600 mg/kg). The APAP-treated animals received either15 ml/kg PBS, 
15 ml/kg DMSO/PBS or 10 mg/kg of the JNK inhibitor SP600125 in 
DMSO/PBS. B. Apoptosis-induced factor (AIF) and Bax protein levels were 
determined by Western blot analysis in the cytosol and mitochondria, 
respectively, from animals treated with APAP and PBS, DMSO or SP600125 










P-JNK in whole liver, AIF in cytosol and Bax in mitochondria were measured 
by Western blot analysis at 4 h after APAP (600 mg/kg). Some animals 









Nitrotyrosine staining as indicator of peroxynitrite formation in mice treated 
with 600 mg/kg APAP for 6 h or 12 h. Some of the animals received PBS, 
DMSO or the JNK inhibitor SP600125 at 1 h before APAP administration. One 
group of animals was treated with the iNOS inhibitor L-N-(1-iminoethyl)lysine 
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Figure 6.8 
A. Hepatic iNOS mRNA expression was measured by real time RT-PCR in 
mice at 4 h and 12 h after 600 mg/kg APAP treatment. Data are expressed as 
the iNOS-to-actin mRNA ratio; the value of untreated control animals was set 
as 1. Some of the animals received 15 ml/kg PBS, 15 ml/kg DMSO/PBS or 10 
mg/kg SP600125 in DMSO/PBS at 1 h before APAP administration. Data 
represent means ± SE of n = 3 animals per group. *P<0.05 (compared to C), 
#P<0.05 (compared to APAP/PBS). B. Western blot analysis of iNOS 
expression in livers of controls or animals treated with 600 mg/kg APAP for 6 
h. One to three representative samples are shown from each group. The 
numbers under the blot show the results of the densitometric analysis. Data of 
control animals were set as 1. C. Plasma nitrate plus nitrite, which were used 
as a marker of NO production, and D. plasma ALT activities were measured at 
6 h after 600 mg/kg APAP or 2 mg/kg lipopolysaccharide (LPS). Some of the 
animals received 15 ml/kg PBS (P), 15 ml/kg DMSO (8.3% in PBS) (D) or 10 
mg/kg SP600125 in DMSO/PBS (SP) at 1 h before APAP administration. An 
additional group was treated with 3.3 mg/kg of the iNOS inhibitor 
L-N-(1-iminoethyl)lysine (NIL) at 0 and 3 h after APAP or LPS administration. 
Data represent means ± SE of n= 3-4 animals per group. *P<0.05 (compared 













Hepatic content of total GSH (GSH + GSSG) (Panel A) and GSSG (Panel B) 
were measured in untreated controls (C) and in animals treated with 600 
mg/kg APAP for 12 h. In addition, the GSSG-to-GSH ratio (Panel C) was 
calculated from each animal. Some of the animals received 15 ml/kg PBS (P), 
15 ml/kg DMSO (8.3% in PBS) (D) or 10 mg/kg SP600125 in DMSO/PBS 
(SP) at 1 h before APAP administration. Data represent means ± SE of n = 4 












P-JNK and β-actin protein expression (Panel A), plasma ALT activities (Panel 
B), and hepatic total glutathione content (GSH+GSSG) (Panel C) were 
measured at 6 h after 600 mg/kg APAP. Some of the animals received 15 
ml/kg PBS (P), 15 ml/kg DMSO (8.3% in PBS) (D) or 10 mg/kg SP600125 in 
DMSO/PBS (SP) at 1 h before APAP administration.  Additionally, some 












Protection against APAP hepatotoxicity by JNK inhibition.  
The main goal of this study was to evaluate the relative importance of several 
potential mechanisms of the involvement of JNK signaling in APAP-induced 
liver injury. JNK activation was monitored by formation of P-JNK due to the 
autophosphorylation of JNK during activation and the fact that JNK can 
phosphorylate a variety of downstream proteins not always to the same 
degree (Wicovsky et al., 2007). Overall, our data showing JNK activation after 
APAP overdose and a protective effect with the specific JNK inhibitor 
SP600125 are in agreement with several previous studies (Gunawan et al., 
2006; Hanawa et al., 2008; Henderson et al., 2007; Latchoumycandane et al., 
2007). Furthermore, the importance of JNK in APAP-induced liver injury was 
demonstrated by the elimination of ASK, an upstream activator of JNK 
(Nakagawa et al., 2008b). Our studies also support the conclusion that in 
contrast to the earlier report (Gunawan et al., 2006) inhibition of JNK2 alone is 
not effective in reducing APAP hepatotoxicity (Bourdi et al., 2008; Hanawa et 
al., 2008; Henderson et al., 2007). In addition, selective elimination of JNK1 
was also ineffective (Bourdi et al., 2008; Gunawan et al., 2006; Henderson et 
al., 2007). However, we did not observe an increase in APAP-induced liver 
injury at the 6 h time point using JNK2-/- mice as was reported by Bourdi et al. 
for 12 -32 h after APAP (Bourdi et al., 2008). Another important observation in 
our study is the fact that the solvent used to administer SP600125 (DMSO in 
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PBS) clearly inhibits the early metabolic activation of APAP and accounts for a 
substantial protection in this model. Although the inhibitor provides a 
significant additional effect, it cannot be excluded that the high efficacy of 
SP600125 may involve some solvent effect. However, since a peptide 
inhibitor of JNK in the absence of DMSO showed similar efficacy as 
SP600125 (Henderson et al., 2007), the effect is predominantly caused by 
inhibition of JNK rather than the initial inhibition of the metabolism.    
 
JNK activation and Bax translocation. Our data indicate that inhibition of JNK 
reduces the mitochondrial translocation of Bax and the release of AIF from 
the mitochondria at early and late time points after APAP administration. The 
effect of JNK on Bax is in agreement with previous reports (Gunawan et al., 
2006; Hanawa et al., 2008). We have previously shown that mitochondrial 
Bax translocation is an early event (beginning at 1 h) after APAP overdose, 
which is responsible for the early release of intermembrane proteins (Bajt et 
al., 2008; Jaeschke and Bajt, 2006). Although the release of cytochrome c 
and Smac does not result in activation of caspases (Knight and Jaeschke, 
2002), the nuclear translocation of AIF and endonuclease G appears to be 
mainly responsible for the characteristic nuclear DNA fragmentation observed 
after APAP (Bajt et al., 2006). Since Bax-deficient mice show a strong 
reduction of intermembrane protein release, nuclear DNA damage and cell 
injury, it can be concluded that these Bax-mediated events contribute to cell 
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death at these early time-points (Bajt et al., 2008). However, mitochondrial 
Bax translocation does not affect the mitochondrial oxidant stress and 
peroxynitrite formation, which subsequently will trigger MPT resulting in 
mitochondrial swelling and rupture of the outer membrane (Bajt et al., 2008). 
At this later time-point, intermembrane proteins are released independent of 
Bax. Thus, even complete elimination of Bax results only in a temporary 
protection against APAP overdose. This means that the protective effect of 
JNK inhibition, which lasts during the first 12-24 h, can at best be mediated in 
part by inhibiting mitochondrial Bax translocation.  
 
The possibility that JNK activation leads to inactivation of the protective Bcl-2 
family members Bcl-2 and Bcl-xL by phosphorylation could also contribute to 
the mitochondrial dysfunction (Latchoumycandane et al., 2007). However, the 
protective role of Bcl-2 in APAP hepatotoxicity has been questioned as Bcl-2 
overexpressing mice show actually higher injury compared to wild type 
animals (Adams et al., 2001). Other mechanisms suggested by which 
inhibition of JNK activation could be protective include the inhibition of Bid 
processing by caspase-8 inactivation (Wang et al., 2006) and downregulation 
of Bad expression (Takamura et al., 2007). However, this appears to be a 
mechanism mainly relevant for TNF-mediated apoptosis. Although not all of 
the individual Bcl-2 family members have been assessed in the APAP model, 
Bid-deficient mice are not protected (H. Jaeschke and X.M. Yin, unpublished) 
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and pancaspase inhibitors do not prevent mitochondrial dysfunction and liver 
injury after APAP (Jaeschke et al., 2006; Lawson et al., 1999) suggesting that 
potential effects of JNK on caspase-8 activation and Bid may not be relevant 
for the injury process.    
 
JNK activation and iNOS induction.  
Peroxynitrite, which is formed by the combination of the two radical species 
superoxide and nitric oxide (NO), is generated in cells undergoing necrosis 
during APAP hepatotoxicity (Hinson et al., 1998). Scavenging of this 
aggressive oxidant and nitrating agent by GSH resulted in a profound 
protection and improved regeneration (Bajt et al., 2003; Knight et al., 2002). 
However, the source of NO is still controversial. An induction of iNOS during 
APAP-induced liver injury has been reported (Gardner et al., 2002; 
Latchoumycandane et al., 2007) but peroxynitrite formation in the absence of 
iNOS induction was also observed (Knight et al., 2001). In the current study 
we found a relevant increase of iNOS mRNA but only a moderate increase in 
iNOS protein expression. Furthermore, no significant elevation of plasma 
nitrite+nitrate levels as indicator of actual NO formation was found. The potent 
iNOS inhibitor L-Nil (Zhang et al., 2000a), which completely prevented the 
endotoxin-induced increase in plasma nitrite+nitrate levels, had no effect on 
the formation of NO or peroxynitrite during APAP hepatotoxicity and did not 
affect liver injury. These data do not support the hypothesis that iNOS-derived 
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NO is critical for APAP-induced peroxynitrite formation and liver injury under 
our present conditions. A potential reason for the limited importance of iNOS 
during APAP-induced liver injury may be the formation of IL-10, which can 
suppress pro-inflammatory gene expression including iNOS thereby reducing 
a potential contribution of iNOS to the pathophysiology (Bourdi et al., 2002). 
Although SP600125 attenuated iNOS mRNA and also the minor increase in 
protein expression, there was no effect on plasma nitrite+nitrate levels. 
Together these data suggest that JNK activation may contribute to a limited 
iNOS induction during APAP hepatotoxicity. However, consistent with 
previous data of us and others (Hinson et al., 2002; Knight et al., 2001), iNOS 
did not play a relevant role and therefore it is unlikely that the profound 
protective effect of JNK inhibition was mediated by effects on iNOS. These 
conclusions are different than those of Latchoumycandane et al. 
(Latchoumycandane et al., 2007). However, these investigators used 
leflonamide, which may have additional effects beyond just inhibiting JNK. 
 
JNK activation and oxidant stress. 
Our previous studies with APAP hepatotoxicity documented the presence of a 
mitochondrial oxidant stress (Jaeschke, 1990; Knight et al., 2001) and 
mitochondrial peroxynitrite formation (Cover et al., 2005b), which preceded 
cell death and occurred as soon as GSH was depleted (Bajt et al., 2004). 
Furthermore, when peroxynitrite was being scavenged and more ROS was 
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detoxified by accelerated recovery of mitochondrial GSH levels initiated by 
treatment with GSH (Knight et al., 2002), JNK activation was prevented 
(Figure 6.1). Likewise, when the mitochondrial oxidant stress is inhibited by 
scavenging of NAPQI by metallothionein induction (Saito et al.), JNK 
activation was prevented (Figure 6.1). These findings suggest that in 
agreement with previous findings (Hanawa et al., 2008), an oxidant stress 
was the main trigger of JNK activation after APAP overdose. The oxidant 
stress most likely does not activate JNK directly but targets upstream events 
such promoting the dissociation of thioredoxin and apoptosis signal-regulating 
kinase 1 (ASK1) (Nakagawa et al., 2008a) or the Ras pathway (Saha and 
Nandi, 2009). Alternatively, JNK can be released from a complex with GST-Pi 
by binding of NAPQI to GST (Elsby et al., 2003). This would be in agreement 
with AMAP treatment not activating JNK (Hanawa et al., 2008) and the fact 
that JNK activation occurs in the cytosol and oxidant stress occurs mainly in 
mitochondria. 
 
Although JNK appears to be activated by the initial oxidant stress, given the 
fact that nitrotyrosine staining of the tissue was eliminated by the JNK inhibitor 
at 6 and 12 h after APAP and that there was no increase of tissue GSSG or 
the GSSG-to-GSH ratio, it can be concluded that SP600125 effectively 
prevented the formation of reactive oxygen species. Since ROS and 
peroxynitrite are mainly formed in mitochondria, this suggested that JNK 
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activation promotes the formation of ROS in this cell organelle. Interestingly, 
the solvent of the JNK inhibitor (DMSO in PBS) did not prevent the oxidant 
stress (judged by GSSG formation) but appears to allow a faster recovery of 
hepatic GSH levels, which seem to scavenge most of the ROS and 
peroxynitrite and thus reduce tissue injury. The effect of DMSO is attributed to 
its inhibitory effect on APAP activation, which limits the injury and promotes 
recovery. Nevertheless, the JNK inhibitor clearly has additional effects that 
prevent the mitochondrial oxidant stress. Hanawa et al proposed that 
translocation of activated JNK may induce MPT (Hanawa et al., 2008). Given 
the time sequence of rapid GSH depletion and mitochondrial dysfunction 
followed by oxidant stress, eventually MPT and then cell necrosis (Bajt et al., 
2004; Kon et al., 2004), it appears that JNK activation enhances the oxidant 
stress and peroxynitrite formation, which subsequently induces MPT. 
Mitochondrial oxidant stress is a potent inducer of MPT (Nieminen et al., 
1997). This does not exclude that JNK can synergistically promote MPT 
through acting directly on proteins involved in MPT (Hanawa et al., 2008). 
However, it appears highly unlikely that JNK inhibition can prevent MPT in the 
presence of a substantial mitochondrial oxidant stress and peroxynitrite 
formation. Further studies are necessary to identify the various targets of JNK 
in the mitochondria. 
 
In summary, JNK activation seems to control, at least in part, the early release 
 168 
of intermembrane proteins and DNA fragmentation through mitochondrial Bax 
translocation. However, the most important effect of JNK activation was a 
profound suppression of peroxynitrite formation, which was not caused by 
inhibition of iNOS induction. In contrast, there was clearly a complete 
elimination of the mitochondrial oxidant stress. Although the exact target of 
JNK in the mitochondria has to be identified, it appears to be upstream of MPT. 
Because of the critical role of oxidant stress and peroxynitrite for the 
propagation of the cell injury mechanisms, especially mitochondrial viability, 
(Figure 6.11) these data demonstrate that JNK could be an important target to 
limit cell injury and liver failure at least during the first 24 h after APAP 
overdose.
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CHAPTER 7: CONCLUSION and CLINICAL RELEVANCY 
APAP-induced hepatotoxicity in patients undergoes 
In England and Wales, there are over 30,000 hospital admissions and about 
150 deaths because of APAP overdose each year (Morgan et al., 2007). In 
the USA, acetaminophen-associated overdoses result in 56,000 emergency 
room visits, 26,000 hospital admissions, and about 450 deaths annually 
(Nourjah et al., 2006). Clinically, there are two causes of APAP overdose in 
patients including unintentional overdose and attempted suicide. In many 
cases of unintentional APAP ingestion, people are using alcohol, hypnotics, or 
illicit drugs in combination with APAP and often are unaware of the risk of 
delaying hospitalization. On the other hand, most intentional overdose 
patients receive medical care within 24 hours of APAP overdose. 
Unintentional overdoses are more frequent than intentional overdoses with 
the median dose being 34 g versus 20 g respectively, but these large doses 
are consumed over an average of 3 days. Once acute liver failure develops, 
the outcome for suicidal or unintentional APAP ingestion is similar (Lee, 
2004).  
The antidote for APAP poising is N-acetylcysteine (NAC), which is a cysteine 
prodrug, and a GSH precursor. Although NAC and cysteine are very similar in 
terms of chemical structure, NAC is less toxic, because it is less susceptible 
to oxidation and it is more soluble in water, which makes it a better source of 
cysteine than administration of cysteine itself (Atkuri et al., 2007). In the clinic, 
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NAC is injected as follows: one loading dose of 150 mg/kg followed by 
maintenance doses of 50 mg/kg every 4 h (Polson and Lee, 2005). Oral NAC 
administration frequently exacerbates the nausea and vomiting associated 
with APAP poisoning itself since the sulfur moiety of NAC gives a “rotten egg” 
smell. In 2004, the Food and Drug Administration approved an intravenous 
NAC administration, Acetadote® which is manufactured by Cumberland 
Pharmaceuticals in Nashville, Tennessee (Whyte et al., 2008). Intravenous 
administration of NAC was associated with reduction of antiemetic effects and 
cost saving (Miller et al., 2007).  
 
Summary and Conclusion 
We investigated three mechanisms of protection against APAP-induced 
hepatotoxicity in this thesis (Figure 7.1) and the following discussion focuses 















a) Mechanism of protection A: preventing NAPQI binding to proteins 
It is well known that the most effective mechanism of protection by GSH or 
NAC is to enhance the scavenging capacity for NAPQI in hepatocytes. This 
prevents modification of mitochondrial proteins and thereby blocks the 
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initiation of APAP toxicity. However, a limitation of this approach in the clinical 
scenario is that GSH or NAC must be administered during the time when 
APAP is being metabolized to NAPQI. By the time APAP overdose patients 
arrive at the emergency room, the metabolism of APAP is over in most cases.   
In aim 2, we demonstrated that zinc induced metallothionein (MT) can 
scavenge some of the excess NAPQI after GSH depletion thereby preventing 
covalent binding to cellular proteins. There are various stimuli to induce MT, 
such as restriction of food intake (Bremner and Davies, 1975), exercise (Oh et 
al., 1978; Shiraishi et al., 1983) in addition to heavy metal, and chemical 
induced MT. Therefore, a non-toxic intervention that induces MT might be 
beneficial for APAP overdose patients.  
 
b) Mechanism of protection B: scavenging of reactive oxygen and 
peroxynitirite 
Covalent binding of NAPQI to mitochondrial proteins leads to inhibition of 
mitochondrial respiration with increased mitochondrial synthesis of reactive 
oxygen species and peroxynitrite formation in mitochondria (Cover et al., 
2005b; Jaeschke, 1990; Knight et al., 2001; Tirmenstein and Nelson, 1990). 
The resulting oxidant stress can activate the c-jun N-terminal kinase, which 
translocates to the mitochondria and may be involved in the further 
aggregation of ROS formation and induction of the mitochondrial membrane 
permeability transition pore opening (Hanawa et al., 2008).  
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 In aim 3, we found that a JNK inhibitor suppressed peroxynitrite 
formation, which was not caused by inhibition of iNOS induction. However, 
there was clearly a complete elimination of the mitochondrial oxidant stress. It 
is probable that JNK could phosphorylate some of the proteins that are 
important for respiration in the mitochondria and inhibit mitochondrial function. 
This might also lead to accumulation of electrons and cause oxidative stress 
in mitochondria. In fact, it has been reported that JNK phosphorylated 
proteins have been implicated in the induction of mitochondrial membrane 
permeability pore in the rat brain (Schroeter et al., 2003). In addition, JNK 
inhibition can protect against APAP-induced disturbance of state III respiration 
(Hanawa et al., 2008). Although further research is required to determine the 
detailed mechanisms, JNK inhibitor may be a promising approach because it 
targets a critical toxic mechanism (ROS formation). In our experience, only 
interventions that target the mitochondria oxidative stress can be successful 
in preventing cell death. In addition, SP600125 was shown to be effective 
even several hours after APAP overdose (Gunawan et al., 2006; Hanawa et 
al., 2008; Henderson et al., 2007; Latchoumycandane et al., 2007).  
  
c) Mechanism of protection C: Mitochondrial energy substrates 
In the 1970s, NAC was used to treat patients with APAP overdose (Prescott et 
al., 1977). Even today, NAC therapy is thought to be the best treatment for 
overdose patients (Polson and Lee, 2005). However, our data from aim 1 
 174 
indicates that GSH confers more efficient protection when compared to an 
equimolar dose of NAC. This effect is clearly caused by the 3-fold higher 
amount of amino acids in GSH compared to NAC, and we demonstrated that 
excess amino acids for metabolism in the Krebs cycle provide the most 
effective reduction of APAP-induced liver injury. Therefore, in addition to NAC 
to promote GSH synthesis, the administration of substrates to support the 
mitochondrial energy metabolism could be a promising supportive strategy to 
limit APAP-induced cell death and liver failure.  
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